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1. List of abbreviations 
1-AGPAT: 1-acylgylcerol 3-phosphate acyltransferase 
AA: Abdominal aorta 
ABC: Adenosine trisphosphate-binding cassette 
AC: Adenylyl cyclase 
ACh: Acetylcholine 
AD: Alzheimer’s disease 
ATX: Autotaxin 
Aβ: β-amyloid 
BAEC: Bovine aortic endothelial cell 
C1P: Ceramide 1-phosphate 
cAMP: cyclic adenosine monophosphate 
CCL2: chemokine ligand 2, also known as MCP1: Monocyte chemoattractant protein-1  
CIB1: Calcium and integrin-binding protein 1 
COX1: Cyclooxygenase-1 
COX2: Cyclooxigenase-2 
CPA: Cyclic phosphatidic acid 
cPLA2: Ca
2+
-dependent intracellular phospholipase A2 
CTRL: Control 
DGPP: Diacylglycerol pyrophosphate 
DMSO: Dimethyl sulfoxide 
DSS: dextran sulfate sodium 
ECL: Extracellular loop 
EDG: Endothelial differentiation gene 
EGF: Epidermal growth factor 




ENPP: Ectonucleotide pyrophosphatase/phosphodiesterase 
ER: Endoplasmic reticulum 
ERK1/2: Extracellular signal-regulated kinase 1/2 
GPCR: G protein-coupled receptor 
GP-PDE/GDE: Glycerophosphodiester phosphodiesterase 
HDAC1/2: Histone H3-histone deacetylase 1/2 
HDL: High-density lipoprotein 
HEV: High endothelial venule 
HIF-1: Hypoxia inducible factor 1 
hTERT: The human telomerase reverse transcriptase 
HUVEC: Human umbilical vein endothelial cell 
IBD: Inflammatory bowel disease 
ICAM-1: Intercellular adhesion molecule-1 




-independent intracellular phospholipase A2 
JNK: c-Jun N-terminal kinase 
KLF2: Krüppel-like factor 2 
KO: Knockout 
LDL: Low-density lipoprotein 
LFABP: Liver fatty acid binding protein 
LPA: Lysophosphatidic acid 
LPAAT: Lysophosphatidic acid acyltransferase 
LPC: Lysophosphatidyl-choline 
LPhoE: Lysophosphatidyl-ethanolamine 




Lyso-PLD: Lysophospholipase D 
mm-LDL: Minimally modified low density lipoprotein 
mox-LDL: Mildly oxidized low density lipoprotein 
MS: Multiple sclerosis 
nat-LDL: Native low-density lipoprotein 





 exchange regulatory factor 2 
NK cell: Natural killer cell 
NMDA: N-methyl-D-aspartate 
NO: Nitric oxide 
NPP: Nucleotide pyrophosphatase/phosphodiesterase 
NUC: Nuclease-like domain 
PA: Phosphatidic acid 
PAR1: Protease-activated receptor 1 
PC: Phosphatidyl-choline 
PDE: Phosphodiesterase domain 
PDGF: Platelet-derived growth factor 
PE: Phenylephrine 
PECAM-1: Platelet endothelial cell adhesion marker-1 
PG: Prostaglandin 
PhoE: Phosphatidyl-ethanolamine 
PI3K: Phosphoinositide 3-kinase 
PKC: Protein kinase C 
PLA1: Phospholipase A1 
PLA2: Phospholipase A2 




PLD: Phospholipase D 
PLD2: Phospholipase D2 
PPARγ: Peroxisome proliferator-activated receptor γ 
PS: Phosphatidyl-serine 
PSNL: Partial sciatic nerve ligation 
PTEN: Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
PTX: Pertussis toxin 
RA: Rheumatoid arthritis 
RBC: Red blood cell(s) 
RGD: Arg-Gly-Asp integrin binding motif 
ROCK: Rho kinase 
S1P: Sphingosine 1-phosphate 
SC: Schwann cell 
SK1: Sphingosine kinase type 1 
SK2: Sphingosine kinase type 2 
SM: Sphingomyelin 
SMase: Sphingomyelinase 
SMB: Somatomedin B-like domain 
SP: Substance P 
SPC: Sphingosylphosphorylcholine 
SPL: Sphingosine 1-phosphate lyase 
sPLA2: Secreted phospholipase A2 
SPP: S1P phosphatase 
TA: Thoracic Aorta 
TGFβ: Transforming growth factor β 




TNFα: Tumor necrosis factor α 
TP: Thromboxane prostanoid receptor 
TRAF2: Tumor necrosis factor receptor-associated factor 2 
TRIP6: Thyroid receptor-interacting protein 6 
TXA2: Thromboxane A2 
TXB2: Thromboxane B2 
VCAM-1: Vascular cell adhesion molecule-1 
VLDL: Very low-density lipoprotein 
VSM: Vascular smooth muscle 
VSMC: Vascular smooth muscle cell(s) 










The term lysophospholipid includes two lipid families with numerous members: the 
glycerophospholipids and the sphingolipids (1). The best-characterized representatives 
of these two groups are lysophosphatidic acid (LPA) and sphingosine 1-phosphate 
(S1P) respectively. 
The first LPA-related publication is from 1957, when Vogt isolated a mixture of lipid 
nature, which elicited contractions in the intestine of rabbits (2). The exact compound 
and structure remained however undiscovered that time. It was only in 1978, when 
Akira Tokumura and his group isolated and identified LPA from soybean lecithin, a 
new lipid mediator that induced hypertension in rats and other species (3, 4). At the 
beginning of the 1990s, Tigyi and Miledi identified albumin-bound LPA as an 
endogenous regulator of cellular functions and proposed that its actions are mediated by 
plasma membrane receptor(s) (5-8). 
Since then, the number of reports on LPA increased rapidly. However, the molecular 
target of LPA actions was unclear until 1996, when Chun and colleagues identified the 
first G protein-coupled receptor (GPCR) of LPA, LPA1 (9). Since that time, five other 
LPA receptors have been described and confirmed (LPA2-6). Moreover, an intracellular 
receptor of the same mediator has also been reported in 2003 (10). 
The first studies with S1P date back to the early 1990s as S1P was established a 
regulator of cell proliferation, growth, and survival (11, 12). Although the first S1P 
receptor itself was described already in 1990 by Timothy Hla and his group (13), it took 
eight years for S1P1 to be de-orphaned and confirmed as an S1P GPCR in 1998 (14, 
15). During the past 20 years, four other S1P receptors were reported (S1P2-5). 
Interestingly, three of the six LPA and all S1P GPCRs belong to the endothelial 
differentiation gene (EDG) family of receptors, sharing several similarities in structure 
and function as well. Studies conducted with human umbilical vein endothelial cells 
(HUVECs) showed, that the transcription of these genes increases upon the 
administration of phorbol-12-myristate-13-acetate, a compound that induces endothelial 
differentiation, hence the name EDG. Subsequently, it was revealed, that the structure of 
the EDG encoded protein shows great similarity to the GPCRs (13). 
Following the early reports, the lysophospholipid field developed rapidly. The 




S1P became well-established mediators in several physiological and pathological 
processes (16, 17). 
Our workgroup has been investigating the vasoactive actions of both mediators since 
the late 2000s. Interestingly, the literature available on both lipids is contradictory (see 
chapter 2.4.5.4.). In case of LPA, we described dual vasoactive effects in isolated 
murine vessels depending on the presence or absence of the endothelium. On the other 
hand, S1P, that had a nearly negligible impact on the diameter of vessels applied alone, 
potentiated the effect of other constrictors.   
Our aim was to describe these phenomena and to explore, with the aid of 
pharmacological and genetic methods, which lysophospholipid receptors and 
downstream signaling pathways mediate these processes. 
In the following, after a summary of our present knowledge on lysophospholipids, 
their receptors and roles in physiology and pathology, I would like to present our results 
on the vasoactive effects of these mediators with special attention on the GPCRs 
involved. 
2.1. Lysophospholipids: nomenclature, molecular structure and natural 
analogues 
2.1.1. Lysophosphatidic acid (LPA) 
LPA (1-O-acyl-2-hydroxy-sn-glycerol-3-phosphate) was first identified as a key 
component of “Darmstoff”, a smooth muscle stimulating substance in 1957 (2, 18). This 
simple, small lipid derives from the plasma membrane. LPA consists of a polar 
phosphate headgroup, a glycerol backbone and a hydrophobic fatty acid tail. Based on 
the acyl-group, LPA can be divided into saturated (e.g.: 16:0, 18:0) and unsaturated 
(e.g.: 16:1, 18:1, 18:2, 20:4) molecular species (Figure 1). 
Because the acyl chains can bind to the glycerol backbone in either sn-1 or sn-2 
position, sn-1 and sn-2 regioisomers can be differentiated respectively. Yet sn-2 isomers 
have a short half-life in vivo, as a relative rapid acyl-migration occurs towards the sn-1 
position resulting in a 9:1 (sn-1:sn-2) equilibrium ratio (19, 20). 
Studies around the millennium revealed the existence of alkyl-ether (21, 22) and 
alkenyl-ether (23) analogues of LPA (Figure 1). These naturally less abundant forms 




showed marked preference for 1-O-alkyl-gylcerophosphate to acyl-LPA of the same 
chain length (26). 
Cyclic phosphatidic acid (1-acyl-sn-glycerol-2,3-cyclic phosphate, CPA) is also a 
naturally occurring analogue of LPA, present in blood (27), however its origin is still 
obscure. CPA also acts as a second messenger, inhibiting the peroxisome proliferator-













Figure 1. A few natural analogues of LPA; LPA 18:1: 1-oleoyl lysophosphatidic acid, AGP 18:1: 1-O-
octadecyl glycerophosphate, Alkenyl-GP: Alkenyl glycerophosphate, modified after G. Tigyi (16) 
 
LPA is present in human plasma in a low nanomolar concentration, however in 
serum it increases to the micromolar range (29, 30). The rank order of LPA species in 
plasma is 18:2>18:1≥18:0>16:0>20:4, whereas in serum 20:4>18:2>16:0≥18:1>18:0 
(31). It is of note that LPA composition of the plasma alters with pregnancy. Palmitoyl-
LPA (16:0) becomes the dominant species, although total LPA concentration of the 
plasma remains unaltered (32). Accumulation of this form is attributed to alteration in 
lysophospholipase D (lyso-PLD) activity, while the unaltered total LPA concentration 
may be a result of the increased general metabolism during pregnancy (32). 
Considering its hydrophobic nature, LPA binds to carrier proteins in biological fluids 
as well as intracellularly (33). These bindings may clarify the contradiction between the 
facts, that, although the plasma concentration of LPA exceeds the Kd of LPA GPCRs, 




Albumin is the most abundant carrier of LPA in blood plasma, binding up to three 
mols of LPA per mol protein. It is noteworthy, that albumin also binds 
lysophosphatidyl-choline (LPC) and lysophosphatidyl-ethanolamine (LPhoE), although 
on a different binding site than LPA (33). Albumin is the most widespread carrier of 
LPA used under laboratory conditions. 
Gelsolin is a protein, discovered in 1979, that has intracellular and secretory forms as 
well. It circulates in human and rodent blood in a concentration of 250±50 mg/l. 
Formerly considered an exclusively actin-binding protein, later proved to be able to 
bind LPA with nanomolar affinity (33). Lind and colleagues proposed a novel, 
remarkable yet speculative hypothesis about the role of plasma gelsolin in inflammation 
(34). In site of injury, activated platelets and leukocytes produce LPA while actin is 
released upon cell lysis. The actin released from dying cells binds to gelsolin, depleting 
it, which makes possible for LPA to act in free, unbound form on defense and repair. 
The same group showed that plasma gelsolin levels decrease dramatically in case of 
critical tissue damage, as in adult respiratory distress syndrome (34). 
Aside of gelsolin another intracellular binding molecule of LPA has been identified: 
liver fatty acid binding protein (LFABP). This protein binds LPA on two distinct sites, 
on which other lysophospholipids (e.g. LPC, LPhoE and lysphosphatidyl-gylcerol) can 
be bound with micromolar affinity. Intracellular concentrations of LFABP range from 
0.2 to 0.4 mM. Besides hepatocytes and intestinal cells, LFABP is also expressed in the 
cells of proximal tubules, where it is assumed to play a role in the reabsorption of 
lysophospholipids (33). 
2.1.2. Sphingosine 1-phosphate (S1P) 
The first reports of S1P were published in the early 1990s, proposing a role in 
intracellular calcium mobilization and cell proliferation (12) in cell growth regulation 
(11) and apoptosis inhibition (35). In contrast to LPA, S1P depicts a single molecular 
species (2S-amino-1-(dihydrogen phosphate)-4E-octadecene-1,3R-diol, Figure 2). S1P 
forms a zwitterionic structure at physiological pH, because the amine group of the 
terminal serine of the sphingosine base is basic at this pH, whilst the terminal esterified 
phosphate group bears negative charge. Besides this zwitterionic head group, S1P, 
similarly to LPA, has a long hydrophobic, aliphatic chain at the other side of the 






Figure 2. Structure of sphingosine 1-phosphate, its precursor sphingosine and its analogue FTY720-
phosphate (Fingolimod-phosphate) (37) 
 
Measured with multiple types of individually developed methods, S1P 
concentrations are estimated to range between 200-400 nM and 500-900 nM in plasma 
and serum respectively (38-41). Being a lipid with a considerably large hydrophobic 
tail, S1P traffic in plasma also requires binding molecules. For a long time albumin was 
postulated to be the sole carrier of S1P, till it has been revealed, that S1P binds 
predominantly to lipoproteins in a rank order of high-density lipoprotein (HDL) > low-
density lipoprotein (LDL) > very low-density  lipoprotein (VLDL) > lipoprotein-
deficient plasma (mainly albumin) (42, 43). Other sources consider the amount of S1P 
bound to LDL and VLDL negligible (44). For a half decade, it remained enigmatic, 
which of the several components of HDL binds S1P, until in 2011 Christoffersen and 
colleagues reported it to be apolipoprotein M that binds approximately 65% of plasma 
S1P (45). HDL is not only a simple carrier of S1P, moreover it seems that HDL, which 
binds approximately 100-200 pmol/mg S1P (42), and S1P form a functional unit with 
distinct functions and signaling (42, 46, 47). Firstly, the Kds of S1P for S1P GPCRs are 
within the 2 to 30 nM range (14, 48), which is markedly lower, than S1P concentrations 
found in plasma and serum. Based on these facts, it has been suggested that, HDL-
binding might prevent full S1P GPCR activation and acts in a protective manner (42, 
49). On the other hand, HDL-bound S1P has been reported to have four times longer 
half-life than that bound to albumin (42, 50), suggesting a protective role for HDL 
against ectoenzymes degrading S1P (49). 
Later it has been revealed, that S1P is at least partly responsible for the anti-
atherogenic, and cytoprotective features of HDL (42, 46). S1P inhibits cell migration in 




exerts more sustained S1P1 agonism, than the albumin-bound form, decreasing tumor 
necrosis factor α (TNFα)-induced nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and intercellular adhesion molecule-1 expression (52). This type of 
agonism of S1P1 might involve other structures, which facilitate the docking and 
entrapment of HDL-bound S1P and prevent endocytosis. However, this aspect of the 
S1P area requires further investigations, as the role of scavenger receptor class B type 1 
occurred in the docking process (53). Besides, the fact, that oxidation of LDL, which is 
well-known to promote pro-atherogenic features of this particle, decreases the S1P- and 
reciprocally, elevates the LPC content of LDL, is also in favor of the anti-atherogenic 
role of S1P (50). 
2.2. Biosynthesis and degradation of lysophospholipids 
Although both mediators can be synthesized intra- as well as extracellularly the 
significance of the two sites differs in case of each lipid. While the bulk of S1P is 
produced intracellularly, with negligible extracellular production, the majority of 
plasma LPA is formed extracellularly (54-57). 
Intracellularly, in mitochondria and microsomes, LPA is an intermediate of 
phospholipid synthesis, thus it is a product of glycerophosphate acyl transferase, which 
esterifies glycerol 3-phopshate with acyl-CoA or that of monoacyl-glycerol kinase as 
well (33). 
Extracellular LPA is a result of three stimulus-coupled synthetic pathways (33). In 
spite of the recent advances in the field of lysophospholipid metabolism, regulation and 
the amount of contribution to extracellular LPA levels of each pathway are still 
questions to be resolved (Figure 3). 
LPA can be generated from phosphatidic acid (PA) by the action of numerous 
enzymes. Although PA is a natural component of biological membranes, it can be a 
product of the cleavage of other phospholipid precursors, such as phosphatidyl-choline 
(PC), phosphatidyl-ethanolamine (PhoE) or phosphatidyl-serine (PS) by phospholipase 
D (PLD). Formation of LPA from PA is catalyzed by phospholipase A1 (PLA1) or 
phospholipase A2 (PLA2) (58, 59). PA specific variants of these two enzymes have been 
described in human (31, 60, 61), porcine (62) and horse (63) thrombocytes. Depending 
on the cleaving enzyme, sn-1 and sn-2 regioisomers are produced by PLA2 and PLA1 




small molecular weight secreted (sPLA2) and intracellular Ca
2+
-dependent and –
independent (cPLA2 and iPLA2 respectively) isoforms, hence this pathway can also 
contribute to intracellular LPA production (64, 65). Our current knowledge implies that 
PA cleavage to LPA contributes up to 10% of extracellular LPA production (31). It is 
assumed that the feasible role of PLA enzymes is to create a pool lysophospholipids for 























Figure 3. The major synthetic pathways of extracellular LPA; PLD: phospholipase D, PLA2: 
phospholipase A2, ATX: autotaxin (66) 
 
Siess and colleagues proposed a still obscure pathway of LPA formation (67). In 




modified LDL (mm-LDL) treatment of human platelets resulted in shape-change, which 
proved to be mediated by LPA, was however absent in case of the native, unoxidized 
form (nat-LDL). Analysis of the lipid composition of nat-, mox- and mm-LDL revealed 
the presence of LPA in the mox- and mm- forms but not in nat-LDL. Thus, LPA 
generation occurs during oxidation of LDL in a Cu
2+
-dependent manner and LPA is the 
main prothrombotic mediator in mox-LDL (67, 68). Besides, the LPA generated in this 
process can also influence the LDL uptake of atherosclerotic plaques via PPARγ 
activation (33). 
Tokumura and colleagues raised first the possibility of LPA generation through lyso-
PLD activity in rat plasma in the 1980s (69), which also gained confirmation in rabbit 
(70) and human (31, 71). The responsible enzyme remained enigmatic until the early 
2000s, when two groups independently reported it to be autotaxin (ATX) (72, 73). 
ATX was first identified as an autocrine motility factor in human A2058 melanoma 
cells, which stimulated motility in numerous tumor cell lines in a pertussis toxin (PTX)-
dependent manner (74, 75). Besides that, high expression of ATX was found in 
neuroblastoma, hepatocellular carcinoma, breast cancer, renal cell carcinoma, 
glioblastoma, non-small cell lung cancer, B cell lymphoma, and thyroid carcinoma  
cells (75). ATX expression proved to be regulated diversely depending on cell lines. 
Studies imply the role of epidermal growth factor (EGF), basic fibroblast growth factor, 
transforming growth factor beta (TGFβ), v-Jun, β-catenin, Wnt-1, α6β4 integrin, and 
Epstein-Barr virus infection in this process (76-82). 
The crucial role of ATX in mammals is well emphasized by the fact, that mice 
deficient in ATX die around embryonic day 9.5 due to fatal vascular defects in embryo 
proper and yolk sack (83). This phenotype is interestingly recapitulated by Gα13 
knockout (KO) mice (84-86). ATX KO embryos also showed severe deficiency in 
neural tube formation and closure (83). Absence in expression of hypoxia inducible 
factor 1 (HIF-1) and its positive regulator Akt proved to have a role of high significance 
in neural tube malformations (75). It is of note, that ATX null embryos have abnormal 
lysosome formation in the visceral endoderm cells of the yolk sack (87). Morpholino 
oligonucleotide studies in zebrafish revealed a direct role of ATX in the formation of 




Since ATX heterozygous mice show 50% plasma LPA levels of that in wild types 
(WT), it has been established, that the bulk of LPA in biological fluids originates from 
ATX-mediated production (83). Multiple types of precursor lysophospholipids (LPC, 
LPhoE, LPS), of which LPC is the most abundant, can serve as substrate to ATX, which 
cleaves the phosphate group, thus forms LPA. 
ATX has been identified as a member of the mammalian ectonucleotide 
pyrophosphatase/phosphodiesterase family (ENPPs or NPPs), which includes seven 
enzymes designated ENPP 1-7. All members of the family are capable of pyrophosphate 
bond hydrolysis, while ATX is unique by also having a lyso-PLD activity (72, 73, 89).  
ATX is a rigid, multidomain structure glycoprotein of 125 kDa, consisting of five 
domains (89) (Figure 4). It includes two N-terminal somatomedin B-like (SMB1 and 
SMB2) domains, a central phosphodiesterase (PDE) domain, a lasso-loop domain, and a 
C-terminal nuclease-like (NUC) domain. Protein-protein interaction among the SMB 
domains and the PDE domain, an N-linked glycan and an interdomain disulfide bridge 
between the PDE and NUC domains, furthermore the fact, that the lasso-loop wraps 
tightly around the NUC domain maintain a high structural rigidity for the catalytic PDE 
domain (90, 91). Similarly to the other members of the family ATX has a conserved 
amino acid residue at Thr
210
 as the substrate binding site and two proximal Zn
2+
 ions 
contribute to the lytic activity (91). Unlike any other ENPP, ATX has a deep, 
hydrophobic lipid binding pocket of 15 Å, situated inside the catalytic domain (91). 
This pocket is suitable for the acceptance of mono- but not of diacyl phospholipids (91). 
Later on, it turned out, that the lack of a 18 amino acid sequence made the formation of 
this pocket possible, which is absent in every other ENPP (90, 91). Conversely, 
insertion of this sequence did not alter the pyrophosphatase activity of ATX but 
significantly alleviated its LPC hydrolysis (91). It is noteworthy, that ENPP 6 
hydrolyses LPC to LPA, while having the 18 amino acid sequence, although it is 
possible that LPC binds to ENPP6 in a different orientation (89). ATX has one other 
feature, missing in other ENPPs, is having a tunnel close to the catalytic domain, which 
forms a so-called T-junction with the substrate binding pocket to which SMB1 also 
contributes (90, 91). The function of this tunnel is still ambiguous. A remarkable 
hypothesis suggests that it could be an exit-site for LPA generated by ATX, releasing its 




hypothesis, ATX has a relatively flat surface around the opening of the tunnel which 
can attach to biological membranes (89). In spite of this appealing hypothesis, the idea 
of this tunnel being an entry-site for the substrate LPC has also been suggested (89). 
Further investigations are required to clarify the role of this unique structure. 
 
 
Figure 4. Autotaxin, a: Domains of ATX, b: Crystal structure of ATX while binding LPC, c: Schematic 
presentation of the active site, the hydrophobic pocket and the tunnel, d: Spherical model of ATX binding 





ATX is known to bind to activated platelets through β3 integrin receptors (54). This 
interaction is attributed to the SMB domains, especially to SMB2, which although 
involves the canonical integrin binding motif (Arg-Gly-Asp (RGD)), it seems, ATX 
binds β3 integrins at a distinct site (90). Besides, ATX binds to chemokine-activated 
lymphocytes via α4β1 integrin (92). The detailed properties of this attachment is still 
elusive, however the PDE domain contains a canonical α4β1 binding motif (Leu-Asp-
Val). Considering the fact, that integrins are not only sole binding molecules but can 
promote intracellular signaling pathways, it is a conceivable assumption that ATX could 
mediate LPA-independent effects through integrins (89). Purification of ATX with 
heparin column chromatography revealed that ATX is able to bind heparin and heparan 
sulfate (89, 93), allowing this versatile enzyme to have further interactions with the cell 
surface and the components of the extracellular matrix. 
Regulation of ATX activity is a field still flooded with questions. In vitro assays 
show ATX a relatively slow enzyme, which does not correlate to the rapid changes of 
LPA levels in biological fluids (89). β3 integrin interactions emerged as potent 
regulators, as overexpression of this kind of integrin in Chinese hamster ovary cells 
resulted in markedly increased LPA production (89). Feedback regulation of ATX is 
also present in vitro by LPA and S1P (89), however this possibility seems to play a 
minor role in vivo (58). 
Unlike to that of LPA, generation of S1P cannot be taken out of context, and should 
be described together with the production of other sphingolipids (Figure 5). De novo 
synthesis of sphingolipids occurs in the endoplasmic reticulum (ER), where ceramide is 
formed via multiple reactions with a rate-limiting step catalyzed by serine 
palmitoyltransferase (94). Ceramide can be phosphorylated by ceramide kinases to 
ceramide 1-phosphate (C1P) or can be converted to sphingosine by ceramidase. 
Sphingosine is the direct precursor of S1P. The reaction is catalyzed by two kinases 
called sphingosine kinase type 1 and 2 (SK1 and SK2 respectively), which are discussed 
below in detail. Conversely, ceramide can be formed from membrane sphingomyelin 
(SM) by sphingomyelinases (SMases), while sphingomyelin synthase catalyzes the 
inverted reaction. Ceramide can also be transformed to complex glycosphingolipids, 




start either de novo or form membrane lipids and since nearly every reaction is 
reversible structural and mediator sphingolipids can rapidly transform to each other. 
It is of interest, while S1P and C1P elicit primarily mitogenic effects (95, 96), 
ceramide and sphingoid bases have mostly pro-apoptotic impacts (97), making the 
regulation of their balance fundamental in view of the cell life-cycle. The entire network 
of these thoroughly regulated processes is described in literature as the “sphingolipid 
rheostat” (Figure 5). 
 
Figure 5. Sphingolipid biosynthetic and degradation pathways after Pitson (98) 
 
SK1 and SK2 are the two enzyme isoforms that catalyze the formation of S1P from 
its direct precursor sphingosine. Although, the two isoforms have overlapping functions, 
and each can compensate the absence of the other, highlighted by reports of mice 
deficient in either of the two enzymes display no obvious phenotypical alteration (99-
101), SK1/SK2 double KO mice die in utero due to severe disruption in angiogenesis, 




Both SKs have splice variants. SK1 has three of them (named SK1a, -b and -c), 
which differ at their N-termini. SK1b has an additional 14 amino acid residue in 
comparison with SK1a, one of which is a cysteine, a putative palmytoilation site, which 
might give an explanation to its constitutive localization to the plasma membrane. The 
role of SK1c, which has an 86 amino-acid long additional residue at its N terminus, 
requires further investigation (57, 102). SK2 has two confirmed splice isoforms (SK2a 
and -b), of which SK2b possesses an additional 36 amino acid-long residue and shows 
higher abundance in a broad range of human tissues. The existence if a third SK2 splice 
variant is reported, however awaits further confirmation (57, 103, 104). It is of note, that 
SK2 contains a 116 amino acid-long insert in its central part, close to the sphingosine 
binding site, which alteration might explain the wider spectrum of artificial substrates 
utilized by this enzyme (105). 
Despite of their importance in sphingolipid metabolism, crystal structure of both SKs 
have not been clarified yet, our knowledge of their structure, motifs and residues are 
based on homology studies with other lipid kinases, mainly diacylglycerol kinases and 
ceramide kinase. SKs cloned from different species contain five conserved regions 
(named C1-C5), which seem to be of grave importance in substrate binding and 
catalysis (106). Inhibitor and homology studies revealed multiple motifs in C1-C3, that 
are critical for nucleotide binding, whilst C5 is assumed to be involved in the catalysis 
of the nucleotide transfer (98). Since C4 is not conserved in diacylglycerol kinases and 
ceramide kinase, it appears to have a role in sphingosine binding (107, 108). 
Investigation with the selective SK1 inhibitor PF-543 clarified the sphingosine binding 
hydrophobic site, named “J-tunnel” due to its shape, which shows only slight 
differences in SK2 (47). More in-depth reviews on the structure of SKs are available 
(47, 98). 
Albeit the two SKs catalyze the same reaction, they exhibit considerable differences 
in subcellular localization and regulation by external stimuli. SK1 normally localizes in 
the cytoplasm. Cytokine or growth factor mediated activation of the extracellular signal-
regulated kinase 1 and 2 (ERK 1 and 2 respectively) results in phosphorylation at 
Ser226, activation and relocalization of SK1 to the plasma membrane (109). 
Translocation of SK1 occurs via interactions with the calcium and integrin-binding 




previously assumed to bind calmodulin (110, 111). Notwithstanding the active 
translocation of SK1 is CIB1-dependent, its retention is mediated by the interaction with 
plasma membrane phospholipids PS and PA (98). S1P produced by membrane-bound, 
activated SK1 either can be exported to the extracellular space, where it can bind to S1P 
GPCRs, or activates intracellular targets, such as tumor necrosis factor receptor-
associated factor 2 (TRAF2) and thus activates NF-κB, exerting pro-survival signs 
(112). In most cases, ERK-mediated activation of SK1 is transient, as protein 
phosphatase 2A dephosphorylates SK1 at phospho-Ser225 (113). Several agonists have 
been associated with SK1 translocation including platelet-derived growth factor (PDGF) 
(114), nerve growth factor (115), insulin-like growth factor (116), TNFα (109), 
immunoglobulin E (IgE) (117), LPA (118), and phorbol-esters (109, 119). Besides, 
numerous protein-protein interactions have been revealed which regulate SK1 activity. 
δ-catenin (120), Lyn kinase (121), Fyn kinase (122), and eukaryotic elongation factor 
1A (123) have been reported to activate, while SK-interacting protein (124), 
aminoacylase 1 (125), platelet endothelial cell adhesion marker-1 (PECAM-1) (126), 
and four-and-a-half LIM only protein-2 (127, 128) inhibit it. 
SK2 activity is also rapidly increased by several agonists, such as TNFα (129), 
interleukin-1β (IL-1β) (129), EGF (130), and FcεRI cross-linking (122). Although the 
SK1 ERK regulatory site Ser225 is not conserved in SK2, it seems, that ERK1/2-
mediated phosphorylation has an activator effect on SK2, however the putative site of 
this action is either Ser351 or Thr578 or both (131). 
SK2 is generally most abundant in cytoplasm and the nucleus, though serum 
starvation and protein kinase C (PKC) activation are reported to facilitate its 
relocalization to the ER (132, 133). Molecular mechanism of this transport is still 
obscure; however, the N-terminus of the kinase appears to have a role in it (134). S1P 
produced by ER-bound SK2 is rapidly transformed to ceramide due to the high 
abundance of the degrading enzyme S1P phosphatase and ceramide synthase in ER 
(132, 135, 136). 
SK2 contains nuclear localization and export signals regulating its translocation into 
and out of the nucleus, of which the latter is activated by protein kinase D-dependent 




It is of note, that SK2 has been reported to induce apoptosis in an S1P-independent 
manner. SK2 contains a BH3 domain, which may be involved in interaction with B-cell 
lymphoma-extra large, release of cytochrome c and caspase-3 activation (137). 
As seen before, regulation of SK2 is quite complex, and albeit a considerable 
knowledge is already available, the bulk of the work of deciphering involved processes 
remains to be done. This is well emphasized by the findings, where phosphoproteome 
analysis of cultured HeLa cells and murine liver tissue conceded at least five new 
phosphorylation sites on SK2 (Ser351, Ser363, Ser368, Ser378 and Ser448) of yet 
elusive function and significance (138-140). 
As both types of SK localize intracellularly, the bulk of S1P is also produced there, 
however more and more studies indicate, that SKs can be released to the extracellular 
environment (141). Constitutive (57, 142) as well as heat stress- (143) and oxidized 
LDL immune complex-induced (144) secretion of SK1 has been reported. On the other 
hand, caspase-cleaved forms of SK2 are released from several types of cells during 
apoptosis (145). Besides, ATX-mediated cleavage of sphingosylphosphorylcholine 
(SPC) has been described (146), which thus leads to extracellular S1P generation, 
however the amount of S1P produced this way is limited due to low plasma SPC 
concentrations (147). 
Although S1P is present in plasma at high nanomolar concentrations (38-41), S1P 
levels are extremely low in most tissues, what generates an in vivo S1P gradient 
between plasma and tissues (148). For a long period, platelets were proposed to be the 
major source of plasma S1P. S1P is stored in these blood constituents in large amounts 
(38, 149), which is also supported by the fact, that thrombocytes are devoid one of the 
major S1P degrading enzyme S1P lyase (SPL) (149, 150). Furthermore, upon 
stimulation by thrombin (151), or shear stress (152), platelets release S1P in a PKC 
dependent manner (149, 151). In contrast with this, mice deficient in nuclear factor 
erythroid 2, a major transcriptional regulator in megakaryocyte development and 
platelet production (153), had normal plasma S1P levels, however had virtually no 
circulating thrombocytes (154). Pappu and colleagues demonstrated in 2007, that 
plasma (but not lymph) S1P predominantly derives from hematopoietic sources, 
primarily from red blood cells (RBCs) (154). Consistently with this, RBCs are reported 




high concentrations (155). According circulating hypotheses, RBCs may release S1P on 
a constant basis, producing a basal S1P level, whereas platelets do it in an activation-
dependent manner, generating high S1P concentrations in the local environment (49). 
Thereafter, studies revealed that every cell is capable of S1P production by 
sphingomyelin metabolism (156), and that endothelial cells also contribute significantly 
to plasma S1P levels (157). 
Since plasma S1P is primarily produced intracellularly and is impermeable to the 
plasma membrane due to its polar head, S1P requires transporters to be able to act in the 
extracellular environment. Numerous members of the adenosine trisphosphate-binding 
cassette (ABC)-type transporter family have been proposed to be responsible for S1P 
release, including ABCC1 (158), ABCA1 (159), ABCG1 (160) and ABCA7 (161, 162). 
Despite supportive pharmacological results, these findings gained no confirmation in in 
vivo studies (163). Interestingly, Spinster2 (Spns2) was identified in zebrafish, was 
shown to be a transporter of S1P and analogue Fingolimod (FTY720). Thus far, it is the 
only S1P transporter molecule, which was confirmed in vitro as well as in vivo (164, 
165). 
Similarly to its synthesis, degradation of LPA can occur in three distinct pathways 
(33). Dephosphorylation of LPA by phosphatases leads to monoacyl-glycerol, while 
removal of the fatty acid chain by lysophospholipases results in the formation of 
glycerol 3-phosphate. LPA can be converted to PA by acyltransferases. 
Phosphate headgroup of LPA can be hydrolyzed by lipid phosphate 
phosphohydrolases (LPPs) of which three isoforms have been described: LPP1 and its 
splice variant LPP1a, LPP2 and LPP3 (166). Since the crystal structure of LPPs has not 
been yet clarified, our information on its orientation, structure, and mechanism of action 
lay predominantly on the analysis of related enzymes chloroperoxidase and 
phosphatidyl-glycerophosphate phosphatase B from Escherichia coli. All members of 
the LPP family are integral membrane proteins with six transmembrane regions. Both 
the amino- and carboxy-termini are located intracellularly, whilst the three conserved 
catalytic domains face the extracellular space. Two of the three catalytic domains (C1 
and C2) can be found in the second extracellular loop, while the remaining one (C3) on 
the third. C1 contributes to substrate recognition, at the same time the other two mediate 




to form homo- and heterooligomers (166). Nevertheless, LPP1 hypomorph mice exhibit 
increased concentration and elongated half-life of plasma LPA, overexpression of the 
same enzyme did not alter LPA levels (166). LPP3 also binds to integrins, but in 
contrast with ATX, on its RGD motif. The integrins recognized by LPP3 are αVβ3 and 
α5β1 (166). Consistently with this, LPP1, which lacks RGD, showed no ability to 
integrin binding (166). Transgenic mice and in vitro studies indicate a significant role 
for LPPs in physiological and pathological functions as vascular development and 
permeability regulation, fur and hair growth, cell cycle modulation, and fertility (166, 
167). Considering the actions of ATX in tumor biology, lower expressions of LPPs 
could be expected in various tumors. In accordance with that, LPP1 and LPP3 
expressions are considerably reduced in breast, lung, and ovarian cancer. In contrast, 
LPP2 showed elevated expression in these types of tumors (166). A feasible explanation 
to that could be the role of LPP2 in cell cycle regulation, i.e. LPP2 facilitates premature 
S-phase entry thus enhances tumor growth (166). 
LPA is hydrolyzed to glycerol 3-phosphate by lysophospholipases, of which LPA 
specific species has been isolated from rat brain (168). 
The third pathway of LPA degradation is PA synthesis by acyl-transferases. These 
proteins belong to the 1-acylgylcerol 3-phosphate acyltransferase (1-AGPAT) or 
lysophosphatidic acid acyltransferase (LPAAT) family of five isoenzymes, labeled 
LPAATα-ε or 1-AGPAT 1-5 (33). Based on the facts, that LPAATα and LPAATβ have 
the highest catalytic activity, and LPAATα favors LPA as acyl acceptor the most, these 
two enzymes assumed to be responsible for the bulk of the intracellular LPA degrading 
process (33).  
Metabolism of the alkyl-, alkenyl- and cyclic analogues of LPA is still poorly 
understood. A serine hydrolase, KIAA1363 (169) and diacylglycerol kinases (170) 
assumed to be involved in intracellular alkyl-LPA generation. CPA is synthesized in 
mammalian cells by phospholipase D2 (PLD2) (28) or ATX (16). However, the in vivo 
relevance of the latter is disputed (16). It is of note, that two recently discovered 
members of the glycerophosphodiester phosphodiesterase family (GP-PDEs or GDEs), 
GDE4 and GDE7 cleave 1-O-alkyl-sn-glycero-3-phosphocholine and LPC, thus 




Extracellular degradation of S1P is also catalyzed by LPPs, which are discussed in 
detail in context with LPA. This reaction leads to dephosphorylation of S1P. Since LPPs 
act extracellularly, they have the most direct influence on plasma S1P levels and thus 
S1P signaling on GPCRs among S1P metabolizing pathways (166). 
Intracellular dephosphorylation of S1P is mediated by S1P phosphatases (SPPs). 
SPP1 and SPP2 are sphingoid base-specific phosphatases located in the ER. SPP2 is 
expressed in embryonic mouse kidney, where it mediates S1P levels along with SKs, 
thus influences kidney development. SPP1 is proposed to have a role in formation of 
ceramide and other sphingolipids in the ER. Since SPP1 is located intracellularly, 
extracellular S1P requires transporters to reach the enzyme. ABC-type transporters are 
assumed to serve this function (56). 
S1P can be irreversibly metabolized by the intracellular enzyme SPL (56). During 
the reaction, the sphingoid base is cleaved at position C2,3, resulting in formation of 
heaxadecenal and ethanolamine phosphate, which products can enter further lipid 
synthetic processes. Even though SPL is a ubiquitously expressed enzyme, there are 
reports of its role in ischemia, radiation and chemical injury of tissues (56). Besides, 
SPL has been shown to be regulated by PDGF signaling (56). 
It is of note, that mice deficient in SPL die around weaning age, exhibiting anemia, 
myeloid cell hyperplasia, and pathological abnormalities of the lung, heart, urinary tract, 
and bone (56). Accumulation of long chain bases and ceramide in neurons and vital 
organs as well as cytotoxic concentrations of S1P may be involved in these phenotypic 
alterations. Moreover, high plasma triglyceride levels and absence of adipose tissue 
found in SPL KO mice surmise abruptions in global lipid metabolism (56). This is 
supported by reports, describing SPL product ethanolamine phosphate being essential 
for functioning of sterol regulatory element-binding proteins  and that SPL KO mice 
showed changes in expression of PPARγ target genes, which contribute to general lipid 
metabolism (56). 
As seen above, multiple pathways are involved in either synthesis or degradation of 
lysophospholipids; however, these processes are well organized and strictly regulated, 






2.3. Lysophospholipid receptors 
Both LPA and S1P have extracellular as well as intracellular targets (16, 56). 
Although, LPA after its discovery quickly emerged as an extracellular bioactive 
lysophospholipid, its mechanisms of action remained elusive. Several early hypotheses 
and theories emerged regarding these mechanisms including membrane perturbation 
(172), calcium chelation (173), and signal transductional pathways involving 
intracellular- and plasma membrane receptors (174-176). The cloning and identification 
of the first LPA GPCR in 1996 set a new era in the lysophospholipid field (9). During 
the past two decades, since the recognition of LPA1, five other LPA receptors have been 
reported (LPA2-6); moreover intracellular targets of LPA also have been confirmed (10). 
In contrast, S1P was already an established intracellular mediator, regulating cell 
growth (11) and suppressing apoptosis (35), when it has been demonstrated that S1P 
acts on cell surface receptors (S1P1-5). All of these receptors are rhodopsin-like GPCR 
with seven transmembrane regions (TMs). 
2.3.1. G protein-coupled lysophospholipid receptors 
Extracellularly LPA can bind to six (LPA1-6), whilst S1P to five (S1P1-5) subtypes of 
GPCRs, specific to the corresponding mediator. Recently, new types lysophospholipid 
receptors have been reported attributed to lysophosphatidyl-inositol (LPI1) and 
lysophosphatidyl-serine (LysoPS1-3) (177). However, this thesis focuses only on LPA 
and S1P GPCR, thus those other receptors will not be discussed here. Three of the six 
LPA receptors (LPA1-3) and all reported S1P GPCRs belong to the EDG family, while 
the remaining three LPA receptors (LPA4-6) are part of the P2Y purinergic cluster (16, 
56, 178). The LPA and S1P GPCRs with their respective signal transduction are 
depicted in figure 6 and 7, respectively. 
During the last five years the crystal structures of three lysophospholipid receptors 
were solved (S1P1, LPA1 and LPA6) (179-181), which provided new aspects to our 
former knowledge of ligand binding and structure-activity properties of these receptors, 
based on homology studies primarily with rhodopsin and β-adrenergic receptors (182-
184). Description of the crystal structure of the first lysophospholipid receptor S1P1 also 
gave a boost to homology studies (179), as S1P1 shared a greater homology with the 




analyze the receptor-agonist/antagonist interaction of the remaining LPA and S1P 
GPCRs more precisely (185). Although these former experiments lead to the 
recognition of multiple interactions between receptor and ligand, they have limitations, 




Figure 6. The six confirmed GPCRs of LPA and the signaling pathways they activate; ROCK: Rho 
kinase, SRF: Serum response factor, PLC: Phospholipase C, IP3: Inositol trisphosphate, DAG: 
Diacylglycerol, PKC: Protein kinase C, MAPK: Mitogen-activated protein kinase, PI3K: 
Phosphoinositide 3-kinase, AC: Adenylyl cyclase, cAMP: Cyclic adenosine monophosphate;  after H. 
Mirendil, M. E. Lin und J. Chun (186) 
2.3.1.1. EDG receptors 
S1P1 (formerly EDG1) was the first recognized member of the EDG family by Hla 
and colleagues in 1990, though at this time unaware of S1P being its cognate ligand, 
thus being an S1P receptor (13). Hecht and colleagues described LPA1 (EDG2) as the 
first lysophospholipid receptor in 1996 (9). Since these early discoveries, all eight 
members of the EDG gene cluster have been reported and validated to be a receptor 




In case of EDG family LPA receptors, three key interactions of ligand binding have 
been revealed. Cationic amino acids (Arg and Lys) of TM3 and TM7 form ion-pairs 
with the phosphate group of LPA, while a Gln of TM3 establishes a hydrogen bond 
with the sn-2 hydroxyl group (33, 183). Further experiments deciphered, that the Arg 
residue of TM3 is conserved in the whole EDG family and also required for S1P 
binding of S1P receptors. Based on more in depth investigations of S1P1, S1P binding 
also depends on three amino acid residues; two Arginines, which make an ion-pair with 
the phosphate group and a Glu of TM3, which corresponds the aforementioned Gln in 
LPA receptors, and interacts the ammonium moiety of S1P (182). Wang and colleagues 
reported that the Gln/Glu residue in TM3 determines LPA/S1P specificity respectively. 
In a range of single-mutation experiments, they showed, if the Gln in LPA1 is mutated 
to Glu, LPA1 is able to bind S1P, on the other hand if Glu of S1P1 is shifted to Gln, 
S1P1 binds only LPA and unable to be activated by its own ligand S1P (183). The 
defined crystal structures of LPA1 and S1P1 also highlighted some intriguing details of 
ligand docking abilities of both receptors. While the extracellular loops (ECLs) and 
TMs of LPA1 are organized in a way that LPA1 accepts ligands from the extracellular 
space, in case of S1P1 the N-terminal with ECL1 and ECL2 forms a cap, which appears 
to block the entry of ligands, approaching this way. On the other hand, TM1 and TM2 
are closer to TM3 than in other GPCRs, which leaves a gap between TM1 and TM7 
making it possible for ligands to enter laterally from the outer leaflet of the plasma 
membrane (179, 180). 
LPA1 (EDG2) is the first identified (9) and most thoroughly studied 
lysophospholipid receptor. In mammalian cells the LPAR1 gene encodes a protein of 
364 amino acids, of which one variant has been reported with an 18 amino acid deletion 
(187). LPA1 has a broad expression profile, in humans it has been detected in brain, 
heart, placenta, spleen, kidney, colon, small intestine, prostate, testis, ovary, pancreas, 
skeletal muscle and thymus (188), while it is highly abundant in murine brain, heart, 
lung, stomach, small intestine, spleen, thymus, testis and skeletal muscle (189). The 
murine Lpar1 gene or formerly ventricular zone gene-1 is highly expressed in the 
neocortical region called ventricular zone of the developing brain (9). The ventricular 
zone disappears before birth but Lpar1 expression persists mainly in cells forming the 




expression of Lpar1 has been detected in oligodendrocytes and Schwann cells (SC), the 
myelinating cells of the central and peripheral nervous systems respectively (190, 191).  
LPA1 KO mice exhibit about 50% perinatal lethality, attributed to abnormal suckling 
behavior, which may be a consequence of impaired olfaction. Besides, KO mice have 
reduced body and brain sizes, craniofacial dysmorphism with blunted snouts and wide-
spaced eyes, and increased apoptosis in sciatic nerve SCs. 2.5% percent of LPA1 null 
embryos showed frontal cephalic hematomas (192). It is of interest, that LPA1 KO mice 
are significantly protected against bleomycin induced pulmonary fibrosis (193). During 
breeding of this KO strain a spontaneous variant emerged named MálagaLPA1 
(maLPA1) named after the place of its discovery (194). Despite negligible perinatal 
lethality, maLPA1 mice show more severe defects in the brain than ordinary LPA1 KO 
mice (194) and exhibit multiple behavioral abnormalities including inhibition of fear 
extinction (195) and aggravation of chronic stress-induced impairment to hippocampal 
neurogenesis (196). 
LPA1 couples to Gαi/o, Gαq/11 and Gα12/13, which can activate a wide range of 
downstream signaling pathways through phospholipase C (PLC), mitogen-activated 
protein kinase (MAPK), Akt, Ca
2+
 mobilization, Rho and Rho kinase (ROCK). LPA1 
can elicit multiple cellular responses including cell proliferation, migration, survival as 
well as cytoskeletal changes, and establishment of intercellular connections (189, 197, 
198). Uniquely among LPA receptors, LPA1 is trafficked to early endosomes, which is 
mediated by C-terminal binding of the GAIP interacting protein (199). LPA has also 
been implicated to regulate the Hippo-Yes-associated protein pathway, however, the 
LPA receptor(s) involved in this process remain(s) unidentified (200, 201). 
Sequence homology investigations of LPA1 led to the identification of LPA2 
(EDG4), a 351/348 (human/murine) amino acid protein coded by the genes LPAR2 and 
lpar2 in human and mouse respectively, which shows ~60% amino acid identity to 
LPA1 (202). Contrary to LPAR1, expression of LPAR2 is quite restricted, showing the 
highest abundance in testis and leukocytes and lower in the prostate, spleen, thymus, 
and pancreas (188). In mice, lpar2 is highly expressed in the kidney, uterus, and testis, 
while moderate levels of mRNA are detected in the lung, stomach, spleen, thymus, 
brain, and heart (203). During development, lpar2 expression has been shown in the 




LPA2 KO mice appear lean with no phenotypic alterations (202). LPA2 null mice 
were however, protected in a colitis-associated tumor model compared to WT mice 
(208), while bronchoalveolar lavage fluid of lpar2 heterozygotes contained reduced 
number of eosinophil granulocytes and lower levels of prostaglandin (PG) E2 (209). 
LPA2 mice show increased sensitivity to genotoxic stress induced by ionizing radiation 
and chemotherapeutics (210) and display delayed resolutions of DNA double breaks 
indicative of impaired DNA damage repair (211). 
LPA1/LPA2 double KO mice have also been generated and showed the same 
phenotype as LPA1 KOs with an increased incidence of frontal hematomas (26% vs 
2.5% for LPA1/LPA2 double KO vs LPA1 KO respectively) (202). These mice, however 
highlighted the opposing effects of LPA1 and LPA2 on primary VSMCs and injury-
induced neointimal hyperplasia, LPA1 being a negative, whilst LPA2 a positive 
regulator of VSMC migration (212). 
LPA2, similarly to LPA1, couples to Gαi/o, Gαq/11, and Gα12/13, through which it can 
initiate the activation of Ras, Rac, phosphoinositide 3-kinase (PI3K), MAPK, PLC, 
diacylglycerol, and Rho pathways (197). LPA2 regulates cell survival and migration. 
Ligands stimulating LPA2 provide protection against exposure to genotoxic stressors 
and protect Lgr5 marker positive intestinal stem cells and hematopoietic progenitor cell 
in the bone marrow (213, 214). The LPA2 PDZ-domain binding motif is unique among 




 exchange regulator factor 2 (NHERF2), which 
activates PLCβ3 and Akt/ERK signaling and inhibits the cystic fibrosis transmembrane 
conductance regulator (215). Mechanistically, LPA2 makes physical interaction with the 
cystic fibrosis transmembrane regulator Cl
-
 channel and due to its coupling to the 
heterotrimeric Gi, protein inhibits cAMP production in the apical compartment of the 
epithelial cell membrane leading to inhibition of Cl
-
 secretion into the lumen (216). This 
mechanism plays an important role and offer therapeutic intervention in the treatment of 
secretory diarrhea caused by activation of this regulator protein (217). LPA2 via its C-
terminal PDZ protein interaction motif and another LIM-protein binding motif forms a 
ligand activation-dependent ternary complex with NHERF2 and the thyroid receptor-
interacting protein 6 (TRIP6). This ternary complex is required for the anti-apoptotic 
effect of LPA2 that is linked to a robust and long-lasting activation of the PI3K-NF-κB 




initiated by the interaction of the receptor C-terminal with TRIP6 (220, 221) and other 
PDZ-domain and zinc-finger proteins (215). The fact, that LPA2 signaling is reported to 
be able to suppress EGF-induced migration and invasion of pancreatic cancer cells, 
raises the possibility of transactivation/cross-regulation between LPA GPCRs and 
tyrosine kinase receptors (222, 223). 
LPA3 (EDG7) was identified by two research groups independently, conducting 
homology studies with LPA1 (224, 225). LPAR3/Lpar3 encodes a 353/354 
(human/murine) amino acid protein with ~54% and ~49% homology to LPA1 and LPA2 
respectively (224). Highest abundance of LPA3 mRNA was found in human heart, 
testis, prostate, and pancreas (224, 225) and murine lung, kidney, uterus, and testis 
(189). Somewhat lower levels were detected in human lung, ovary, and brain (224, 225) 
as well as in murine small intestine, brain, heart, stomach, placenta, spleen, and thymus 
(189). Lpar3 is also expressed in heart, mesonephros, and in three spots in the otic 
vesicle during development (204). 
LPA3 KO mice appear normal; however, KO females show delayed embryo 
implantation, altered embryo spacing, and reduced litter size (226). 
LPA3 couples with Gαi/o and Gαq/11 through which mediates Ca
2+
 mobilization, 
adenylyl cyclase (AC) inhibition and activation of PLC, and MAPK (227). Uniquely, 
LPA3 has been reported to show marked preference for sn2 isoforms of LPA and for 
those containing unsaturated fatty acids (24, 224). 
LPA3 seems to play a role in determining vertebrate left-right patterning. 
Downregulation or inhibition of LPA3 or ATX resulted in disruption of asymmetric 
gene expression and organ asymmetry in zebrafish (88). 
Although S1P1 (EDG1) was the first identified member of the EDG family by Hla 
and Maciag in 1990, it was designated as an orphan GPCR until 1998, when two 
research groups independently confirmed S1P as its specific agonist (13-15). The 
human S1P1R gene encodes a 381 amino acid GPCR (13). High amount of S1P1 mRNA 
was detectable in murine brain, heart, lung, liver, and spleen, while lower levels were 
found in kidney, thymus, and muscle specimens. Murine testis, stomach, and small 
intestine express S1P1 in negligible amounts (228, 229). It is of note, that S1P1 is highly 





Classical S1P1 KO mice show a striking phenotype, as they die in utero between 
embryonic days 12.5 and 14.5 due to massive intraembryonic hemorrhage and edema 
throughout the body and limbs. These mice exhibited abnormal vascular maturation 
despite of normal angio- and vasculogenesis, which can be attributed to a disruption in 
VSMC and perycyte migration resulting in inadequate ensheatment of endothelial cells 
in nascent blood vessels (230). Generation of endothelium-specific S1P1 null mice 
applying the Tie2 Cre-loxP system highlighted the fact, that the severe alterations seen 
in classical KOs are caused by the lack of S1P1 in endothelial rather than VSM cells 
(231, 232). 
Investigation of other tissue-specific KO mice lead to the recognition of the role of 
S1P1 in lymphocyte trafficking. Studies of T-cell specific S1P1 null mice showed, that 
S1P1 is crucial for mature T-cells to egress from the thymus, moreover hematopoietic 
deletion of the receptor caused the same defect of T- as well as B-cell egress (233-235). 
It is of note, that S1P1 is the sole lysophospholipid receptor, targeted by an already 
FDA-administered drug (236). 
S1P1 exclusively couples with Gαi/o and can activate ERK, PLC, and can cause Ca
2+
 
mobilization and inhibit AC (237). Besides S1P1-elicited PI3K/Akt and Rac activation 
have been shown to mediate cell proliferation, survival, migration, and changes in 
cytoskeletal structure (36, 238, 239). Studies with mouse embryonic fibroblast cells 
implicated cross-talk between S1P1 and PDGF signaling, with the latter being upstream, 
which is also supported by the fact, that PDGF receptor KO mice recapitulate the 
phenotype of classic S1P1 KO (240, 241). 
S1P2 (EDG5) was first isolated from rat cardiovascular and nervous systems, later 
confirmed by multiple groups being specific for S1P. The murine S1pr2 gene encodes a 
352 amino acid GPCR (242-244). S1P2 is ubiquitously expressed, including murine 
heart, lung, thymus, brain, liver, kidney, spleen, and adipose tissue (229, 245). In the 
brain, S1P2 expression is the highest at embryonic age and decreases throughout 
development, reaching an almost undetectable level at adulthood (229, 243, 246-248). 
S1P2 KO mice exhibit no obvious phenotypical abnormality, however show a slight 
yet significant decrease in litter size, which was augmented in S1P2/S1P3 double KO 
animals (249). Studies with these mice revealed progressive vestibule-cochlear loss with 




inner ear and sensing hair cell loss in the organ of Corti (250). Besides KO mice showed 
seizure activity (247), disruption in wound healing (251), and in vascular function (252, 
253), as well as reduction in inflammatory cell infiltration and pathological 
neovascularization in ischemia-induced retinopathy (253). Further investigation of S1P2 
KO mice on Apoe
-/-
 background demonstrated that S1P2 signaling is pro-atherogenic 
(254). Furthermore, the zebrafish homologue of the mammalian S1pr2 gene proved to 
be essential for cardiac development, however this phenotype was not observed in mice 
(249, 255). 
S1P2 couples with Gαq/11, Gαi/o, and Gα12/13 through which induces serum response 
element, ERK, c-Jun N-terminal kinase (JNK), P38, PLC, Rho, and PIP3 phosphatase 
(PTEN) activation and mediates cell survival, rounding, and proliferation (256). It is 
noteworthy, that S1P2 inhibits cell migration through the activation of PTEN, which is 
in contrast with S1P1 action (257). 
S1P3 (EDG3) was first cloned as a 378 amino acid orphan human GPCR, later 
proved to be (like S1P2) a high affinity S1P and a low-affinity SPC receptor (197, 258). 
Expression of S1P3 was detected in murine spleen, heart, lung, thymus, kidney, testis, 
brain, and skeletal muscle (229, 245) as well as in human heart, placenta, kidney, liver, 
pancreas, skeletal muscle, and brain (258). 
S1P3 KO mice appear lean, with a small but significant drop in litter size (245). 
However, deletion of S1P3 disrupts a certain amount of S1P actions in the 
cardiovascular system like negative chronotropic and hypertensive effects as well as 
vasoconstriction in basilar artery and nitric oxide (NO)-dependent vasodilation (245, 
259). S1P3 deficiency also prevented HDL-elicited vasodilation, highlighting the role of 
S1P3 in the regulation of the vascular tone (260). Besides, S1P and HDL proved to be 
protective in myocardial ischemia/reperfusion injury through the activation of both S1P2 
and S1P3 (261). 
Although S1P3 shows greater homology with S1P1, its signaling resembles to that of 
S1P2, as S1P3 couples with Gαi/o, Gαq/11, and Gα12/13 and activates ERK, serum response 
element, Rho, and Rac through which mediates cell proliferation, survival, migration 
and rounding (198, 262). It is noteworthy, that in mouse embryonic fibroblast cells S1P3 




It is of note that S1P3 can act as a downstream effector of the protease-activated 
receptor 1 (PAR1). In this manner, S1P3 signaling is involved in LPS-induced IL-1β and 
tissue factor production, which is an essential component in the pathogenesis of sepsis 
(263). 
S1P4 (EDG6) was first isolated from in vitro differentiated human and murine 
dendritic cells (264). The 384/386 amino acid (human/murine respectively) orphan 
GPCR later proved to be specific for S1P (265, 266). Expression of S1P4 is restricted to 
hematopoietic and lymphatic tissues (264). 
S1P4 KO mice appear without any phenotypical abnormality. However, a significant 
amount of megakaryocytes in these animals showed aberrant, non-grained cytoplasm 
with vacuoles. Furthermore, they exhibited delayed recovery after monoclonal 
antibody-induced thrombocytopenia, without any reactive thrombocytosis compared 
with wild-type mice. Nonetheless, megakaryocyte count in bone marrow, platelet count 
in peripheral blood, plasma thrombopoietin level, and bleeding time were normal in 
S1P4 null animals, implying a role for S1P4 in the later phase of megakaryocyte 
maturation (267). Further studies with these animals suggested a role for S1P4 in 
neutrophil trafficking, and pro-inflammatory cytokine release (268) as well as in CD4
+
 
T cell signaling (269). 
S1P4 couples with Gαi/o, Gα12/13 and possibly Gαs, and can activate ERK, PLC, AC, 
Rho and small Rho family GTPase Cdc42. S1P4 influences cell stress fiber formation 
and migration as well (198, 262). 
S1P5 (EDG8) was isolated from rat pheocromocytoma (PC12) cells and identified as 
an S1P receptor at the beginning of the second millennium (270, 271). The rat variant 
encodes a 400 amino acid GPCR (270). Expression of S1P5 is restricted to the brain, 
spleen, and peripheral leukocytes in humans and the brain, skin, and spleen in mice and 
rats (245, 270, 271). In rat brain, S1P5 is localized predominantly to the white matter 
tracts and cells of oligodendrocyte lineage, suggesting a role in proper myelination 
(271, 272). 
S1P5 KO mice were generated and appear lean without any phenotypic difference 
(272). In vivo studies however highlighted the role of S1P5 in natural killer cell (NK 




distribution upon S1P5 ablation (273). Besides, S1P5 expression has been shown to be 
co-mediated with NK cell maturation (274). 
S1P5 couples with Gαi/o, and Gα12/13 through which mediates AC inhibition, Ca
2+
 
mobilization and, in contrast with other S1P receptors, ERK and cell migration 
inhibition (245, 271, 275, 276). 
 
 
Figure 7. S1P GPCRs and activated signaling pathways; AC: Adenylyl cyclase, PI3K: Phosphoinositide 
3-kinase, PLC: Phospholipase C; after C. O’Sullivan and K. K. Dev (277) 
 
2.3.1.2. Non-EDG family LPA receptors 
Although description of the EDG LPA receptors clarified a large amount of the 
extracellular actions of LPA, there are several responses, including platelet aggregation 
and certain aspects of vascular development that could not be fully explained by the 
three EDG family LPA GPCRs (278, 279). In 2003, Noguchi and colleagues, using 
ligand screening by Ca
2+
-mobilization assay, identified a previously known GPCR, 
P2Y9 of the purinergic cluster, as an LPA receptor (280). This observation gave new 
momentum to the lysophospholipid field, and till 2009 two other GPCRs were found to 
be specific to LPA (281-284). These receptors (LPA4, LPA5 and LPA6 in order of 
confirmation) all belong to the P2Y purinergic family, however none of them responds 




binding properties of LPA6 (181). During their research, Taniguchi and colleagues 
found that LPA6 possesses a gap between TM4 and TM5, which forms vertical cleft 
open towards the plasma membrane. Besides, the presence of several hydrophobic 
amino acids in the cleft indicates its role as a lipid-binding site. They speculate that 
LPA6, in contrast with LPA1, can be accessible for its ligands from the extracellular 
environment as well as laterally from the plasma membrane. Considering the fact, that 
the ligand-binding pocket of LPA6, formed by TM3, TM4 and TM5 is highly conserved 
in the P2Y family, binding properties of LPA6 may provide insight into these functions 
of the other two non-EDG LPA receptors as well (181). 
LPA4 (formerly P2Y9 and GPR23) was the first LPA receptor identified, that does 
not belong to the EDG family (280). LPAR4 encodes a 370 amino acid GPCR and is 
located on chromosome X (178). LPA4 shows high abundance in human ovary, lower 
abundance in thymus, pancreas, brain, heart, small intestine, testis, prostate, colon, 
spleen, and platelets (66, 285). Among murine tissues, LPA4 is present in heart, ovary, 
skin, thymus, and bone marrow (66). During development, LPA4 is found in brain, 
maxillary process, branchial arches, limb buds, liver, and somites (204). 
LPA4 KO mice do not exhibit any obvious phenotypical alteration (286). However, 
approximately 30% of the embryos do not survive gestation, which can be attributed to 
hemorrhage and abnormal, dilated blood vessels with abrupt VSM and perycyte 
recruitment (279). Besides, LPA4 is also assumed to have a role in lymphatic vessel 
development, as null mice show dilated lymphatic vessels and lymph sacs (279). 
Furthermore, LPA4 KO mice display increased trabecular bone volume, number, and 
thickness, which are in contrast with what has been seen in LPA1 KO, suggesting 
counteracting roles for LPA1 and LPA4 in bone formation (287). 
LPA4 couples with Gα12/13, Gαq/11, Gαi/o, and uniquely among LPA receptors Gαs as 
well (288). Through these G proteins, LPA4 can trigger Rho/ROCK activation, 
intracellular cyclic adenosine monophosphate (cAMP) accumulation, and ERK and 
PI3K activation (288-290). LPA4 facilitates cell adhesion via N-cadherin and, in 
contrast with other LPA GPCRs, e.g. LPA1, inhibits cell migration (286, 289). 
LPA5 (formerly GPR92) was first identified as an LPA receptor in 2006 (281, 282). 
LPAR5 encodes a 372 amino acid GPCR, which is highly expressed in human spleen, 




and platelets (281, 285, 291). In mice LPA5 mRNA shoes high abundance in small 
intestine, whilst moderately high in lung, heart, stomach, colon, spleen, thymus, skin, 
liver, platelets, mast cells, gastrointestinal lymphocytes, and dorsal root ganglia (281, 
282). LPA5 expression is high in the early embryonic forebrain, rostral midbrain, and 
hindbrain; however later on (from embryonic days 9.5-12.5) the expressional pattern 
becomes more diffuse throughout the whole brain (204). 
LPA5 KO mice appear lean; however, they seem to be protected against neuropathic 
pain, caused by partial sciatic nerve ligation (PSNL) (292). 
LPA5 couples with Gα12/13, and Gαq/11, through which elicits neurite retraction, stress 
fiber formation, receptor internalization and intracellular Ca
2+
 mobilization respectively 
(282). LPA5 has been reported to increase intracellular cAMP levels in a presumably 
Gαs-independent manner (281, 282). It is of note, that LPA5 shows a marked preference 
for alkyl-LPA analogues (25, 26). Besides LPA5 can interact with NHERF2, through 




 exchanger 3 to the microvilli of the 
colon, and facilitates Na
+
-dependent water resorption (293). 
LPA6 (P2Y5) is the most recently identified LPA receptor described by Pasternack et 
colleagues in 2008 (283). Expression of LPA6 was reported in human intestinal mucosa 
cells, scalp hair follicles and skin (283, 294). Currently LPA6 is the only non-EDG LPA 
receptor with an available crystal structure (181), which was briefly covered in the 
introduction of this section. 
LPA6 KO mice have been recently reported. Although these mice exhibited normal 
blood pressure and heart rate, they showed decreased vascular responses to adrenergic 
stimuli by phenylephrine or noradrenalin. Furthermore, LPA6 KO mice showed 
abruption in postnatal retinal vessel formation, indicating that LPA6 signaling is 
essential for the development of the normal vasculature (295). 
LPA6 signaling is still obscure, however evidences suggest, that LPA6 couples with 
Gα12/13 and Gαi/o and can activate Rho, ROCK, PLC, Ras, and PI3K on the other side 
inhibits AC (284, 294, 296). LPA6 has been shown to have marked preference for sn2 
regioisomers of LPA (294). 
At the time of its characterization, LPA6 was reported to be a genetic risk factor for 
an autosomal recessive form for hypotrichosis simplex and woolly hair (283, 297). 




that produces sn-2 LPA also proved to cause the same condition (298, 299). These 
results hint a possible future role for LPA6 signaling in the therapy of human hair loss. 
Homozygous inactivation of LPA6 has been reported in bladder cancer (300). 
2.3.2. Intracellular lysophospholipid targets 
Besides the GPCRs detailed above, both LPA and S1P can act on intracellular targets 
(16, 17). Since S1P is generated inside the cells, the biosynthetic pathways of S1P 
acting intra- and extracellularly do not differ. On the contrary, the bulk of plasma LPA 
is produced extracellularly primarily by ATX as has been covered in previous sections 
thus, and since the majority of circulating LPA is albumin-bound (16), and 
transmembrane migration of albumin-bound LPA is minimal. Thus, intracellular LPA is 
generated in a different manner compared with extracellular, mainly through the action 
of Glycerol-3-phosphate acyltransferases (16). 
2.3.2.1. Intracellular actions of LPA 
McIntyre and colleagues reported in 2003, that LPA activates PPARγ, an essential 
regulator of lipid and glucose homeostasis (10). There are three different PPAR 
isoforms, labelled as α,β/δ and γ (301). PPARγ itself has two isoforms PPARγ1 and 
PPARγ2 (302). PPARγ1 is ubiquitously expressed, whilst PPARγ2 is restricted to 
adipose tissue (303). Deletion of the γ1 isoform causes embryonic lethality (304), while 
that of γ2 results in minor alterations in lipid metabolism (305). In case of its activation, 
PPARγ forms a heterodimer with the retinoid X receptor α (RXRα) and together they 
bind to the peroxisome proliferator response element in the promoter region of the 
target genes, through which regulate their transcription.  In the absence of an agonist, 
the nuclear receptor co-repressor 1 and silencing mediator of retinoic acid and thyroid 
hormone receptor bind the heterodimer and repress its action (306-309). 
Unlike LPA GPCRs, PPARγ is stereoselective and can only be activated by S-
isomers carrying unsaturated acyl chains. Besides, alkyl-LPA analogues are more potent 
activators of PPARγ than acyl ones, a feature shared with LPA5 (16, 310, 311). 
LPA, activating PPARγ, increases the transcription of enzymes involved in 
lipogenesis, lipid storage, and adipocyte differentiation. It means, that the accumulation 




storage, instead of β-oxidation. Under pathophysiologic circumstances, this regulation 
may have a role in the development of non-alcoholic fatty liver disease (16, 312, 313).  
It is of note, that synthetic agonists of PPARγ, the thiazolidinediones are applied in 
the therapy of type 2 diabetes. 
CPA, a naturally occurring LPA analogue, on the other side is an antagonist of 
PPARγ (28). 
Yoshida and colleagues described first, that LPA induces neointima formation in a 
non-injury infusion model of rat carotid artery (314). LPA was injected through the 
external carotid artery into a segment of the common carotid artery that was previously 
ligated, rinsed free of blood and maintained at near physiologic pressure. A 1 h 
exposure to LPA induced neointima formation. This process occurred only if 
unsaturated species of LPA was applied (314). Others concluded that the effect was 
PPARγ-dependent, as GW9662, a specific inhibitor of PPARγ, abolished the neointima 
formation (310). 
PPARγ enhances the transcription of the CD36 scavenger receptor as well, which 
facilitates oxidized LDL uptake of the vessel walls (10). 
PPARγ, along with LPA1 and LPA3, also has a role in mast cell and dendritic cell 
differentiation. In these cells, LPA (and cardiolipin), through the regulation of CD1 
expression, can influence antigen presentation, however this hypothesis needs more 
evidence to be confirmed (315, 316). 
Apart from PPARγ, LPA can attach to multiple actin-binding proteins, like gelsolin, 
formin, adseverin, and villin. These interactions can have a role in the regulation of the 
cytoskeleton (16). 
2.3.2.2. Intracellular actions of S1P 
Since its discovery, S1P has been known to promote cell survival and inhibit 
apoptosis (11, 35). Furthermore, studies showed that S1P elicits Ca
2+
-release from the 
ER (17). However, the mechanism of these actions remained elusive. Recently, several 
intracellular targets of S1P have been identified, which highlighted the importance of 
S1P signaling not only through GPCRs, but via intracellular targets as well. 
As discussed formerly, SK2 has nuclear localization and export signals and can be 
translocated to the nucleus (133, 135). Interestingly, it has been revealed, that SK2 




deacetylase (HDAC) 1/2 bound to the promoter of certain genes. Moreover, S1P 
generated by SK2 binds to HDAC1/2 and prevents histone deacetylation, thus enhances 
transcription of genes including the cyclin-dependent kinase inhibitor p21 and the 
transcriptional master regulator c-Fos (317).  
Furthermore, in fibroblasts, nuclear S1P can stabilize the human telomerase reverse 
transcriptase (hTERT), which is the catalytic subunit of the telomerase complex and 
maintains telomeres, that is often seen in transformed cancer cells. S1P binding of 
hTERT blocks its interaction with the makorin ring finger protein 1, which itself is an 
E3 ubiquitin ligase, thus S1P interaction with hTERT prevents the proteasomal 
degradation of this transcriptase, thus maintaining telomerase activity. Although the 
exact molecular explanation is still lacking, it appears, that S1P binding of hTERT 
mimics its phosphorylation at Asp 684 (318). 
Intracellular S1P, produced by SK1 can directly target the TRAF2 (112). This 
protein is an essential adaptor for the regulatory ubiquitination of receptor interacting 
protein, which is critical in activation of NF-κB in response to TNFα. It was previously 
shown, that TNFα stimulates the association of SK1 and TRAF2, which increases the 
activity of the former (319). Besides, ligase activity of TRAF2 was detectable only in 
presence of S1P but not that of dihydro-S1P. These findings may also explain the fact, 
that dihydro-S1P although is equally potent on S1P GPCRs, in contrast with S1P it has 
no cytoprotective effect (112). 
S1P, produced in mitochondria by SK2, can bind to prohibitin 2, a protein necessary 
for mitochondrial assembly and function (320). The importance of this interaction is 
emphasized by the fact, that mitochondrial respiration is reduced in SK2 KO mice, due 
to the presence of an abnormal form of cytochrome c oxidase with low activity (320). 
In neurons, S1P was shown to modulate the activity of β-site amyloid precursor 
protein cleaving enzyme-1, which is the rate-limiting step in amyloid-β peptide (Aβ) 
production. SK1 inhibition or downregulation, as well as overexpression of S1P-
degrading enzymes decreased the activity of the aforementioned enzyme. Besides, 
Alzheimer’s disease (AD) patients exhibited upregulation of SK2, hinting a possible 





2.4. Roles of lysophospholipids in physiological and pathological responses 
2.4.1. Lysophospholipids in the nervous system 
Lysophospholipids have a pivotal role in the nervous system. This is well 
demonstrated by the fact, that the firs identified lysophospholipid receptor, LPA1, was 
isolated from the ventricular zone of the murine brain (9). Since that, both LPA and S1P 
became well-established regulators in development, physiological function, and 
pathologies of the nervous system (322-324).  
2.4.1.1. Neural development and function 
Neural progenitor cells (NPCs) are located in the ventricular zone of the developing 
brain and undergo several steps including proliferation, differentiation, maturation, and 
migration to form nascent neurons (322, 323). LPA1, LPA2, and LPA4 show marked 
expression in NPCs (206). In vitro and ex vivo studies implicate, that LPA1 signaling 
controls cell proliferation and differentiation, playing a key role in development of the 
cortex of the brain. LPA1 KO NPCs lack migration, proliferation, differentiation, and 
morphological changes essential to neurogenesis (192, 325). Ex vivo studies show that 
LPA2 also has a role in LPA-induced survival and differentiation (326). The importance 
of LPA1 is well emphasized by the phenotype of LPA1 KO and the more severe 
developmental defects of maLPA1 KO mice, described in detail in the previous chapter. 
Our knowledge of S1P in neurodevelopment is much scanter. Although all S1P 
receptors are expressed in NPCs (248), only S1P1 KO mice exhibit abruption in 
neurogenesis with increased cell death and decreased proliferation (101). 
In post-mitotic neurons, LPA mediates neurite retraction, and growth cone collapse, 
however the receptor dependency is still obscure (46). On the other hand, Nerve growth 
factor can activate S1P production via SK1, which then elicits neurite extension in an 
S1P1-dependent manner; however, overexpression of S1P2 or S1P5 inhibited this effect 
(115, 327). Besides, both LPA and S1P signaling have multiple roles in synaptic 
transmission, reviewed extensively (322, 324). 
Astrocytes express LPA1-5 and S1P1,3,4,5 (46). It is of interest, that the injection of 
either LPA or S1P causes astrogliosis in vivo (46). Oligodendrocytes and Schwann cells 
(SCs) are the myelinating cells of the central and peripheral nervous systems 




of interest that LPA1 expression correlates to oligodendrocyte maturation stage. In 
addition, LPA increases myelin basic protein mRNA levels and myelin formation in 
vitro (46). On the other hand, S1P, through S1P5 mediates process retraction, inhibits 
migration, and promotes survival of mature oligodendrocytes. In SCs, LPA is a well-
established survival factor, acting on LPA1 coupled to Gαi/o, PI3K, and Akt. Besides, the 
same receptor regulates actin cytoskeletal rearrangements and enhances cell-to-cell 
adhesion via Rho and ROCK. LPA1 signaling was also demonstrated in SCs in vivo, as 
LPA1 KO mice exhibited increased apoptosis of the sciatic nerve SCs (46). 
Microglia are the resident macrophages of neural tissues, which, upon stimulation, 
activate neuro-inflammatory processes. Microglia express LPA1-3 and S1P1,2,3,5, which 
may alter cell activation. Besides, both S1P and LPA are able to mediate a multitude of 
cellular responses in microglia, reviewed elsewhere (46, 322). 
2.4.1.2. Role of lysophospholipids in neural pathologies 
Both LPA and S1P are involved in multiple processes in neural pathophysiology; 
however, this thesis does not focus on these responses, hence this chapter highlights 
only some aspects of lysophospholipid actions in the neural diseases, which are either 
well-documented or raise the possibility to use lysophospholipid analogs as future 
drugs. 
2.4.1.2.1. Multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized 
by chronic inflammation, demyelination and axonal loss, as well as damage of the 
blood-brain-barrier leading to infiltration of lymphocytes and other immune cells (328). 
Efficacy of FTY720 (Fingolimod) in MS patients shed light on the role of S1P signaling 
in this disease (329). FTY720 is a sphingosine analogue, that is phosphorylated by SK2 
(100, 330) and so is modulator of four of five S1P receptors, S1P1,3,4,5 (331, 332). 
Mechanism of Fingolimod action is attributed to its effect on T-lymphocyte S1P1, 
functioning as an antagonist and causing receptor internalization, through which 
lymphocytes fail to egress from secondary lymphoid organs (333-335). However, 
compelling amount of data has been presented, which implicates, that lymphocyte-S1P1 
signaling is not the only site of action of FTY720 (336). Fingolimod did not alleviate 




experimental autoimmune encephalitis, notwithstanding, the decrease in peripheral 
leukocyte count was present, showing, that FTY720 had an effect on T-lymphocytes 
(336). Besides, microglia get activated in experimental autoimmune encephalitis, which 
was absent in central nervous system-specific S1P1 KO mice on application of FTY720 
(336). It is also assumed, that Fingolimod improves blood-brain-barrier function 
through a yet unknown mechanism (322, 329). FTY720, under the name Gilenya has 
been approved in the relapsing-remitting form of MS in 2010 in Europe, US, and 
several other countries and is still the sole approved drug, targeting a lysophospholipid 
receptor (337). Unfortunately, it failed in trials with the primary progressive form of 
MS, which require alternative forms of therapy (329). 
2.4.1.2.2. Ischemia 
It is of note, that in case of ischemic stroke, S1P levels in the infarct area, as well as 
LPA levels in plasma increase (59, 338, 339). SK2 is upregulated in ischemic brains, 
however not in transient ischemia, where no changes of SK1/2 expression were shown 
(340-342). Furthermore, a subsequent study established SK2 as a protective factor 
(342). Interestingly, LPA1, and LPA2 expression is upregulated during retinal ischemia-
reperfusion injury (343). FTY720, detailed in the previous part, on the other hand, 
proved to reduce brain damage in certain models (322). These data highlight the 
importance of lysophospholipid signaling in ischemic lesions of the central nervous 
system, however also show, that our knowledge is still quite rudimentary in this area. 
2.4.1.2.3. Neuropsychiatric disorders 
The role of lysophospholipids occurred early, as LPA1 KO mice exhibited multiple 
traits as olfaction problems, craniofacial dysmorphism, failure in pre-pulse inhibition of 
the startle reflex, and learning, as well as memory deficiencies, commonly seen in 
autism and schizophrenia (344). Furthermore, maLPA1 KOs show several behavioral 
abnormalities as general anhedonia, anxiety, and stress hypersensitivity (196, 345). 
Consistent with this, LPA1 is downregulated in blood lymphocyte of human 
schizophrenia patients (346). 
LPA signaling has been assumed to have a role in several molecular and 
neurotransmitter pathways, linked to neuropsychiatric functions, including glutamate 






dependent protein kinase II activity (323). Notwithstanding, a study showed, that LPA 
exposure to the cortex elicited anhedonia, anxiety, and depression-associated 
immobility in adult mice, traits also seen in LPA1 KOs (347). Moreover, cortical 
administration of LPA in high concentrations to embryos in the period of neurogenesis 
leads to fetal hydrocephalus (see in a later part in detail) (348). 
On the other hand, much less is known about S1P in neuropsychiatry. However, S1P2 
KO mice showed anxiety and disruption in spatial memory (349). 
2.4.1.2.4. Alzheimer’s disease 
AD is a neurodegenerative illness associated with dementia that affects millions of 
mostly elderly people all around the world (350). AD is a progressive disorder with a 
loss of specific neuron population and is characterized by senile plaques composed of β-
amyloid (Aβ) and aggregated tau protein (350). 
Enzymes of LPA and S1P production ATX and SK2 respectively, have been reported 
to be upregulated in brain specimens of AD patients (321, 351). 
On the contrary, S1P was reported to reduce the activity if BACE, the enzyme 
responsible for the accumulation of abnormal Aβ in AD (321, 352). In AD patients, 
decreased levels of S1P and Aβ-induced downregulation of SK1 action were reported 
(353), and in consistence, SK1-dependent reduction of Aβ-induced cell death (354). 
These results imply the role of S1P in AD is far away from being established, further 
studies hopefully clarify its protective or neurotoxic nature, pointing to possible drug 
targets in S1P signaling pathways. 
2.4.1.2.5. Fetal hydrocephalus 
Fetal hydrocephalus is a common neurological disorder of newborns with prenatal 
hemorrhagic events, and is associated with dilated ventricles, enlarged head, and third 
ventricle and aqueduct occlusion (355). 
Yung and colleagues reported in 2011, that injection of either blood or LPA into the 
lateral ventricle of fetal brains induced hydrocephalus, with the clinical characteristics 
of fetal hydrocephalus in humans (348). Inhibition of LPA1/3 by Ki16425 or lack of 
LPA1&2 prevented the formation of hydrocephalus, which showed the putative role of 




LPA1 and LPA signaling in fetal hydrocephalus but proposed a new model of the 
disorder as well. 
2.4.1.2.6. Neuropathic pain 
Neuropathic pain is a condition, commonly caused by nerve lesion or inflammation, 
and is often associated with lowered nociceptive threshold and consequent allodynia 
and hyperalgesia (356). Hypo/dysesthesia is also frequently seen in neuropathic pain 
(356). Additionally, demyelination can be detected in almost all cases, which presumed 
to have pathologic role in this disorder (356). Clinically, neuropathic pain can 
accompany chronic diseases like diabetes or MS; however can occur as a side effect of 
chemotherapeutical drugs (357). 
LPA signaling is involved in multiple levels in the initiation and maintenance of 
neuropathic pain. This issue has been broadly reviewed (356-358); hereby it is intended 
to highlight the main aspects of LPA and its receptors in this process. 
There are multiple animal models addressing neuropathic pain, including PSNL, 
intrathecal LPA injection, UVB irradiation, and ischemia induced pain (358). 
Interestingly, mice lacking LPA1 or LPA5 are protected against neuropathic pain 
induced by PSNL (292, 359). These studies shed light on the role of LPA summarized 
by the hypothesis of Ueda and colleagues (356, 357). As a result of nerve injury, large 
amounts of glutamate and substance P (SP) are produced and released by primary 
afferent neurons, which act on N-methyl-D-aspartate (NMDA) and neurokinin 1 
receptors respectively. Activation of neurokinin 1 leads to Ca
2+
 mobilization via the 
conventional Gαq/11 pathway, whilst NMDA promotes Ca
2+
 influx. The elevated 
intracellular Ca
2+
 concentration directly activates cPLA2 and indirectly, through 
calcium influx factor (CIF) iPLA2, which produce LPC from PC in the plasma 
membrane. As ATX is abundant in the cerebrospinal fluid, the LPC, produced via the 
aforementioned mechanism, is rapidly converted to LPA (356, 357). 
LPA, through LPA1 is involved in demyelination, as LPA1 KO exhibit no 
demyelination in the PSNL model (359). Further studies deciphered, that LPA1 
signaling has multiple roles in this phenomenon. In SC, LPA1 activates Gαq/11 and 
enhances intracellular Ca
2+
 concentrations. Calpain is a Ca
2+
-dependent protease, that is 
activated upon LPA1 agonism and induces the proteolysis of myelin-associated 




activating the Gα12/13-Rho-ROCK pathway, elicits JNK activation, which on one hand 
through PTEN activity, inhibits Akt-mediated myelination, on the other hand, enhances 
the transcription of c-jun, which downregulates the expression of Egr2 and downstream 
myelin protein myelin-associated protein, myelin basic protein, myelin protein zero, and 
peripheral myelin protein 22. LPA-mediated demyelination subsequently leads to 
induction of axonal sprouting, as axonal surfaces become free of inhibition of the 
myelin sheath. Sprouting of these axons establish connections between nociceptive and 
sensory fibers, which may be the pathophysiological basis of the sensory symptoms in 
neuropathic pain (356, 357). 
In dorsal root ganglion neurons, LPA1 upregulates the levels of several proteins, 
involved in molecular regulation of pathologic pain, like α2-δ unit of N-type Ca
2+
 
channels, and ephrinB1 (356). EphrinB1, acting on its receptor Eph, mediates function 
and trafficking of NMDA receptors, influencing synaptic plasticity (356). 
LPA, via LPA3, also activates astrocytes and microglia; these two cell types seem to 
be involved in the initial process of neuropathic pain. LPA generation induces further 
elevation of LPA levels in a feed-forward manner, activating microglia LPA3 receptors 
and possibly PLA2 enzymes (356, 357). 
It is noteworthy, that LPA5 KO mice do not exhibit neuropathic pain in the PSNL 
model (292). Interestingly, there was no difference in demyelination or other protein 
levels mediated by LPA1, however cAMP response element binding protein showed 
decreased phosphorylation (292). Further studies will reveal the significance of LPA5 in 
this disorder. 
As seen from the above, the presence of LPA signaling is well established in the 
pathogenesis and pathophysiology of neuropathic pain. These studies point out several 
points of action as possible future drug targets; however, many questions remain to be 
answered to gain a better understanding of this field. 
2.4.2. Lysophospholipids in immune function 
Both LPA and S1P perform several roles in immune cell processes, which are 
reviewed extensively divided by cell type elsewhere (46, 269, 360). As immunological 
actions of lysophospholipids are not in the focus of the present thesis, a few well-
described roles of S1P and LPA will be listed in the physiological and pathological 




2.4.2.1. Lysophospholipids in immune cell trafficking 
As already mentioned previously, S1P through S1P1 signaling plays a key role in 
lymphocyte (both T and B) egress from the thymus and secondary lymphoid organs 
(269). The main driving force behind this is the S1P gradient between plasma, lymph, 
and the tissues. Plasma S1P is mainly of erythroid origin and is the highest, while the 
lymph contains S1P in lower concentrations originating almost exclusively from 
lymphatic endothelial cells. Tissues have usually the lowest levels of S1P, due to high 
S1PL activity. The gradient is a result of coordinated and strictly regulated function of 
S1P synthesizing, degrading, and transport proteins, discussed in detail previously 
(269). 
In case of T and B cells, as well as NK T cells, expression of S1P is also required for 
egress. Therefore, S1P expression is thoroughly regulated in these cells. Krüppel-like 
factor 2 (KLF2) is a transcriptional factor, that regulates S1P1 expression, driving its 
upregulation (269). During T cell maturation, driven by KLF2 S1P1 expression 
increases, whilst after T cell activation S1P1 mRNA levels decrease, which is assumed 
to be the result of ubiquitination and degradation of KLF2 (269). S1P expression is also 
regulated through agonist-induced downregulation. High concentrations of S1P elicit 
internalization and degradation of S1P1. It is of note, that Fingolimod is much more 
effective in inducing this phenomenon than the natural agonist (269). Underlying 
mechanisms involve the action of GPCR kinase 2, which phosphorylates the receptor at 
a serine-rich region of the C-terminal and initiates its internalization (361, 362). 
Modulation of S1P1 expression also happens through protein-protein interaction. CD69 
is a C-type lectin, expressed on lymphoid cells right after their activation. If T cells are 
activated by type I interferon stimulation, the increase in CD69 expression 
downregulates S1P1 (269). 
Two hypotheses exist regarding the control of immune cell egress (269). The first 
one is the so-called lymphocyte-centered hypothesis, which implies, that lymphocytes 
sense the S1P gradient via S1P1 expression, which drives them out of the lymph nodes. 
CCR7 –chemokine receptor-mediated retention signals are counteracting forces against 
S1P-S1P1 signaling (269). The other hypothesis emphasizes the role of endothelial 
S1P1. In this model, lymphocyte egress happens constitutively under physiological 




of egress (269). The evidence in support of both hypotheses is somewhat controversial. 
S1P1 agonism-induced block (e.g. FTY720) and the lack of antagonism-induced egress 
block are in favor of the endothelium-centered hypothesis (363-365). However, the 
facts, that lymphocytes lacking S1P1 could not egress from lymph nodes, and decreased 
S1P1 expression results in decreased rate of egress, as well as the lack of S1P 
production through conditional deletion of SK1 and SK2 blocks egress, support the 
lymphocyte-centered view (154, 233, 235, 366). Further experiments are needed with 
decisive evidence in favor of one or the other hypothesis, or a new integrated hypothesis 
should be developed that resolves the above described controversies. It is noteworthy, 
that S1P also mediates NK cell mobilization, although in an S1P5-dependent manner 
(273). 
In contrast to S1P, LPA is assumed to interfere in T cell homing in high endothelial 
venules (HEVs) (360). Constitutive expression and secretion of LPA-producing enzyme 
ATX has been confirmed in HEV endothelial cells in 2008 (92, 367). Furthermore, 
ATX can bind to the plasma membrane of lymphocytes in either an integrin-dependent 
or independent manner, where it converts membrane LPC to LPA. It is however 
disputed, if the locally accumulated LPA drives lymphocytes to the lymph nodes or the 
LPA generated this way acts on the endothelial cells (360). Considering, that HEV 
endothelium expresses LPA1 and LPA4, LPA induces cytoskeletal redistribution, and 
inhibition of ATX disrupts extravasation but not lymphocyte accumulation in HEV, the 
second option seems more plausible (367-369). 
Apart from these effects on immune cell trafficking, it is noteworthy, that both 
mediators have been established in various immunological pathologies as rheumatoid 
arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. For 
more in depth reviews on this issue see: (178, 361). 
2.4.3. Lysophospholipids in the reproductive system 
2.4.3.1. Female reproduction 
Involvement of LPA in reproductive functions has been known for almost 30 years 
(16). Studies in the early 90’s identified LPA-mediated oscillatory Cl
-
 currents in 
Xenopus oocytes (5, 7). Since then, LPA signaling has been described in almost every 




maturation, acrosome reaction, oviduct contraction, early embryo development, and 
uterine smooth muscle contraction (370). Besides, LPA concentration in follicular fluid 
in healthy females is approximately double of that in serum (371). LPA-production is 
also elevated during pregnancy (32). 
The most thoroughly investigated aspect of LPA in reproduction is though the role of 
LPA3 in implantation. LPA3 KO mice have delayed embryo implantation, embryo 
crowding, and reduced litter size. The fact, that transfer of WT embryos into LPA3 KO 
dams reproduced this phenotype argued in favor of a maternal role for LPA3 (226). 
Interestingly, mice deficient in COX2 showed the same defects. Moreover, LPA3 KO 
mice exhibited low expression of COX2 and suppressed levels of prostaglandin end-
products PGE2 and PGI2 in embryonic day (E3.5) which is generally the day of 
preimplantation (226). Exogenously applied PGE2 and PGI2 could rescue the delayed 
implantation and reduced litter size but not the defects in embryo spacing, suggesting 
the role of different prostaglandins or non-prostaglandin mediators in the process (372). 
Besides, expression of LPA3 in the murine uterus was restricted to the luminal 
epithelium and showed a peak at the preimplantation time point, in contrast to other 
lysophospholipid receptors, which are constitutively expressed in all layers of the uterus 
(373). In agreement with the murine data, expression of LPA3 in human uterus changes 
with the menstrual cycle showing highest mRNA levels during early and late secretory 
phase (374). Surprisingly, expression of LPA3 is upregulated by progesterone and 
suppressed by estrogen (16, 226, 372). Conversely, deletion of LPA3 leads to elevated 
ratio of progesterone signaling/estrogen signaling (375). It is also of interest, that LPA3 
KO mice showed delayed collagen clearance and decreased expression of matrix-
degrading metallo- and serine-proteinases in the uterus at E3.5 compared with WT 
animals. These results demonstrate the involvement of LPA3 in the dynamic remodeling 
of uterine extracellular matrix in the peri-implantation period (376). 
As described above, disrupted LPA3 signaling may have a role in the pathogenesis of 
diseases like non-receptive endometrium, placenta previa, placenta accrete, and certain 
types of infertilities (16, 370). 
Our knowledge of the role of S1P in female reproduction remains incomplete in 




ovulation, early embryo development through anti-apoptotic effects, and regulating 
placental trophoblast differentiation and vascular tone (370). 
2.4.3.2. Male reproduction 
Mice deficient in LPA1/2/3, which are highly expressed in the murine testis (189), 
exhibited testosterone-independent decreased germ cell survival, mating activity, and 
higher prevalence of azoospermia in aging mice (377). As for S1P, it has been reported 
to be a survival factor for germ cells (378). Besides, it contributes to erectile function, as 
S1P has been demonstrated to potentiate acetylcholine (Ach)-mediated relaxation in 
human corpus cavernosum strips, in a Ca
2+
-independent manner, through the Akt-eNOS 
pathway (379). 
As previously demonstrated, both LPA and S1P have well-established roles in 
reproduction, however this field still requires intensive investigation, in order to assign 
new points of intervention for managing certain reproductive disorders. 
2.4.4. Lysophospholipids in tumor biology 
Both LPA and S1P were implicated in oncology, as the precursor of LPA, LPC was 
detected in elevated levels in the serum of ovary carcinoma patients (66), and anti-
apoptotic functions of S1P were described shortly after its discovery (17). 
2.4.4.1. Cell proliferation, tumorigenesis 
Ovarian cancer patients not only exhibited elevated levels of LPC in serum, but 
markedly increased concentrations of LPA in ascites samples (16). Furthermore, a role 
of LPA in tumor biology is also implicated by the fact, that aberrantly increased 
expression of ATX was detected in several tumor types including breast cancer, 
glioblastoma, renal cell carcinoma, and hepatocellular carcinoma, responsible for the 
formation of high LPA concentrations locally in the tumor microenvironment (380). In 
addition, ATX itself was identified first as a motogen factor for melanoma cells in 1992; 
however, that time its Lyso-PLD activity was unknown (74). 
LPA acting on its GPCRs can promote cell proliferation through Gαi-RAS-MAPK, 
and Gα12-JNK pathways and LPA signaling was associated with cyclin D1, c-Myc and 
β-catenin activation (380). In addition, LPA via PI3K-Akt signaling enhances cell 




migration (380). It is of interest, that in certain Burkitt lymphoma and melanoma cell 
lines LPA2 was implied to mediate cell survival via Gαs (380). On the other hand, LPA 
receptor signaling was shown to inhibit major tumor suppressor p53 (380). 
Among LPA GPCRs, LPA2 is assumed to have a relevant role in 
tumorigenesis/tumor-progression, as LPA2 KO mice seem to be protected in DSS-model 
of colon cancer (208). Wnt/β-catenin is thought to be of grave importance in this type of 
tumors, in which Wnt-signaling prevents the degradation of β-catenin by the protein 
complex, formed by adenomatous polyposis coli, axins, casein kinase 1α, and glycogen 
synthase kinase 3. β-catenin, if remains intact, can interact with its partner proteins in 
the nucleus and promote the transcription of genes encoding c-Myc and cyclin D1, thus 
aiding cell proliferation. LPA2 takes part in this process by inhibiting glycogen synthase 
kinase 3, via Gαq-PLC-Ca
2+
-PKC (381). Further evidence supporting the role of LPA2 
in colon cancer is provided by the study, in which deletion of LPA2 in APC
min/+
 mice, a 
genetic model of human familial adenomatous polyposis, significantly attenuated the 
initiation and progression of colon cancer (382). 
LPA2 activation also increases the concentration of VEGF locally, which is essential 
for novel vessel-formation and thus propagation of tumors. VEGF in return induces 
ATX expression, leading to LPA production, establishing a potential feed-forward loop 
involving LPA2, VEGF, and possibly LPA4 signaling (16). 
LPA2 was also implicated in regulation of urokinase and MMP expression, enzymes, 
which are key players in the invasiveness of primary tumors (16). 
As already discussed in previous chapters, the effect of S1P on cell proliferation and 
motility cannot be taken out of context, as the ratio of pro-apoptotic ceramide and anti-
apoptotic S1P determines the influence of the sphingolipid rheostat on cell-survival. 
Alterations of sphingolipid producing and metabolizing enzymes in multiple types of 
cancer have been widely reviewed elsewhere (383). Here, some direct connections 
between S1P signal transduction and certain oncological diseases will be highlighted. 
Pro-oncogenic S1P signaling happens dependently as well as independently of S1P 
receptors. The role of S1P1 occurred in colitis-associated colon cancer, via the NF-κB-
IL-6-STAT3 pathway (384). The same receptor acting on PI3K and Rac can have pro-
migratory, pro-invasive functions in Wilms’ tumor (384). In fibrosarcoma cells, S1P1 




thus, it increases invasiveness of these tumors (384). Furthermore, S1P1 has been 
associated with neovascularization, as S1P1 KO mice die in utero between embryonic 
days 12.5 and 14.5 due to severe vascular malformations (230).  
S1P2 is the only receptor, which has pro- as well as anti-oncogenic roles (384). S1P2 
signaling enhances the transcription of master transcription factors c-Jun and c-Fos, 
arguing for its proliferative role (384). On the other hand, S1P2 KO mice show frequent, 
spontaneous development of diffuse B-cell lymphomas with age (384). The signaling 
responsible for these pathologies is however still unknown. 
S1P3 is the most abundant of the five S1P receptors in human breast cancer cell lines. 
Furthermore, it activates Notch to expand the aldehyde dehydrogenase
 
positive cancer 
stem cell population, which is assumed to be crucial in tumorigenesis (384). 
S1P4 and S1P5 have less well-established roles in oncology. Although, S1P5 can 
activate PI3K-Akt-Polo-like kinase 1, which is generally considered to be pro-
oncogenic, inhibitory functions of S1P5 also occurred (384). 
Independently of its receptors, S1P activates intracellularly HDAC1 and 2 and 
hTERT (17). The relevance of these enzymes has been addressed in the chapter 
discussing intracellular S1P actions. 
2.4.4.2. Metastasis 
Both LPA and S1P have been implicated in metastasis. 
Bone metastases are dreaded complication of many types of tumors including breast, 
prostate, kidney, thyroid, and lung cancers. Bone metastases are categorized as 
osteolytic and osteoblastic lesions, corresponding for sites with excessive loss or 
formation of bone tissue respectively (385). Latest evidence suggests that tumor cells do 
not directly evoke bone loss or formation, but influence the functioning of osteoclasts, 
osteoblasts, and osteocytes. Several studies pointed out the possible contribution of LPA 
to osteolytic lesions and some to osteoblastic ones. The knowledge available is 
excellently reviewed elsewhere (386). Here the hypothesis, based on the results 
concerning the role of LPA in bone metastasis, will be briefly summarized. LPA, 
present in a high concentration at the location of metastatic sites, due to platelet 
activation and/or high ATX expression of metastatic cancer cells, acts on the cancer 
cells, increasing the production of factors that influence osteoblast and osteoclast 




released upon LPA stimuli. It inhibits osteoclasts and simultaneously stimulates 
osteoblasts. In case of osteolytic lesions, LPA stimulates  the production of Dikkopf 1, 
IL-6, IL-8, GM-CSF, monocyte chemoattractant protein 1 (MCP1) (also known as 
chemokine ligand 2 CCL2), and Groα by metastatic cells, which increase phagocytic 
activity and maturation of osteoclast and inhibit osteoblast activity (386). 
LPA has a direct effect on bone cells, promoting osteoclast differentiation, survival, 
and bone resorption. LPA1/3 receptors may be involved in this process, as the LPA1/3 
antagonists Ki16425, and VPC32183 inhibited formation and propagation of osteolytic 
metastases in vitro and in vivo as well (386). Simultaneous inhibition of LPA GPCRs 
and ATX by BrP-LPA is also a promising approach for future therapies of these types 
of metastases (386). 
The involvement of S1P in metastasis formation is highlighted by the fact that the 
deletion of Spns2, the ubiquitous S1P transporter reduced the lung metastases of various 
types of cancer cell lines injected in murine tail vein (387). Deletion of SK1 decreased 
the occurrence bladder cancer and melanoma metastases. S1P2 was shown to repress 
breast cancer metastasis suppressor 1 a suppressing factor of metastases, which was 
reactivated upon application of sonepcizumab, an anti-S1P antibody. Furthermore, S1P 
activates the ezrin-radixin-moesin proteins, through which increases motility and 
invasion, features of high importance for metastases. S1P3 was also shown to promote 
metastasis in lung cancer, influencing the TGFβ-SMAD pathway (383). 
2.4.4.3. Resistance against chemo- and radiotherapy 
LPA2 does not only play a role in tumorigenesis of ovary carcinoma, but studies 
suggest it may also contribute to its resistance against chemotherapeutical drugs. LPA2, 
via its C-terminal, promotes certain anti- and inhibits other pro-apoptotic processes. The 
LPA2 C-terminal can bind TRIP6 as well as NHERF2 and these proteins bind each 
other as well. Additionally, NHERF2 forms a homodimer with another NHERF2 
molecule. This complex enhances and prolongs the activation of ERK1/2 and Akt, 
mediators of cell survival and proliferation. Furthermore, LPA2 binds the Siva-1 
transcription factor through its C-terminal. Siva-1 is a pro-apoptotic factor, downstream 
of p53 which, when bound to LPA2 in a ligand-activated mechanism gets 




Siva-1, LPA2 impedes the pro-apoptotic answer of the cell, triggered by p53, upon 
DNA-damage, for instance in case of cytotoxic chemotherapeutical agents (16). 
Additionally to LPA, S1P may also contribute to the development of chemo- and 
radioresistance. In case of colorectal cancer, overexpression of SK1 was correlated with 
intrinsic or acquired cetuximab-resistance. Conversely, inhibition of S1P GPCRs, by 
FTY720, sensitized this type of cancer to cetuximab (388). Excessive expression of 
SK1 was also associated with imatinib- and nilotinib-resistance in chronic myeloid 
leukemia, via inhibition of protein phosphatase 2A by S1P2. Interestingly, application of 
Fingolimod, but not that of Fingolimod-phosphate, restored imatinib-sensitivity in 
chronic myeloid leukemia (389). The aforementioned phenomenon could be the result 
of a direct interaction between FTY720 and protein phosphatase 2A, as S1P2 is the only 
S1P receptor on which FTY720 has minimal or no effect (337). Likewise, silencing 
SPP1, an S1P metabolizing enzyme, by miR-95, enhanced resistance against radiation 
in breast and prostate cancer cells (390). Furthermore, high expression of S1P3 was 
correlated with tamoxifen-resistance in human breast cancer cells (391). 
This short summary highlights the potential of both lysophospholipid mediators to 
point out future drug targets, however further intensive research of the field is inevitable 
to gain a clear view of the roles of certain receptors and their signal transductional 
pathways. 
2.4.5. Lysophospholipids in the cardiovascular system 
The early reports by Tokumura and colleagues in the late seventies already 
established a role of importance for LPA in the cardiovascular system (3, 4, 392). Since 
then, LPA emerged as a key player in multiple aspects of vascular pathology. The other 
lysophospholipid S1P and its receptors also proved to have physiologically relevant 
interactions with the cells of the circulatory system. 
2.4.5.1. Vascular development 
The roles of both mediators in developmental steps of the vasculature have been 





2.4.5.2. Atherosclerosis and atherothrombotic events 
The first investigation that associated LPA with atherosclerosis derives from Siess 
and colleagues back in 1999, when they described the accumulation of LPA in human 
atherosclerotic plaques (67). Since that time, LPA has been described to affect almost 
every cell type involved in this process (393). 
LPA acts on the endothelium, and so enhances cell migration, and upregulates the 
expression of adhesion molecules, such as intercellular adhesion molecule-1, E-selectin, 
and vascular cell adhesion molecule-1 (VCAM-1) (393, 394). Secretion of chemokines 
like CXCL1 and CCL2 also increases (393). LPA is hypothesized to have a biphasic 
role, as it promotes the secretion as well as transcription of CXCL1 in an LPA1/3- and 
NF-κB-dependent manner, respectively (395). Furthermore, LPA promotes endothelial 
permeability in an LPA1-dependent manner, as mice deficient in LPA1 showed 
decreased vascular leakage in a bleomycin-induced lung injury model (193). However, 
other studies supported the role of LPA in stabilizing the endothelial barrier function 
(393). 
Early stages of atherosclerosis include the migration and dedifferentiation of VSMCs 
(396). LPA has been shown to promote migration as well as this shift from contractile 
to pro-inflammatory, secretory phenotype and to enhance SMC proliferation via LPA1, 
including Gαi, Gαq, PKC, ERK1/2, PI3K/Akt and MAPK cascades (393). LPA1, Gαq, 
Gαi and MAPK also mediate the migratory effect of LPA (393). At the same time, the 
activation of LPA1 upregulates the expression of pro-inflammatory cytokines IL-6, 
CCL2 and facilitates the production of NADPH-oxidase-dependent reactive oxygen 
species (ROS) (393). Besides, downregulation of the contractile proteins occur, in an 
LPA3-depednent pathway (397, 398). On the other hand, activation of the intracellular 
LPA receptor PPARγ attenuates neointima formation after vascular injury (393), whilst 
inhibition of LPA3 by Ki16425 diminished neointimal hyperplasia after carotid wire 
injury. Unsaturated LPA species mobilized smooth muscle progenitor cells from bone 
marrow in a pathway linked to CXCL12. This process could be interrupted by silencing 
either LPA1 or LPA3 (399). 
LPA also influences monocytes, recruitment of which into the vessel wall is a crucial 
step in plaque formation (400). It enhances mox-LDL-uptake of 




macrophages. Upregulation of the scavenger receptor A via LPA1/3 intensifies lipid 
accumulation in these cells. Activation of PPARγ in monocytes increases the expression 
of other scavenger receptor CD36 (393). While deletion of PPARγ in macrophages 
promoted atherosclerosis. LPA on one hand evokes monocyte migration, and inhibits 
reverse transmigration, which results in an entrapment of monocytes in the plaque 
(393).  
It is noteworthy, that LPA may also have a role in acute atherothrombosis on basis of 
ruptured plaques. Activated platelets bind ATX via β3 integrins and thus facilitate LPA 
production from LPC as discussed previously. Although thrombocyte activation has 
been implicated to be a major source of local LPA production, the exact mechanism is 
still obscure. 
Former studies suggested a multistep process, in which intracellular- and secreted 
PLA enzymes produce the precursor for ATX (mainly LPC), which binds to the 
platelets and generates LPA; however, the exact PLA isoenzyme was still lacking (393). 
Bolen and colleagues described a new PLA, secreted from activated platelets. The 
enzyme, acyl-protein thioesterase 1, also known as lysophospholipase A-I has PLA1 
activity, thus produces sn2 lysophospholipids, which then undergo acyl-migration as 
previously mentioned. The sn1 lysophospholipids generated this way are well-known 
substrates of ATX (401) and explain the dominance of 18:2 and 20:4 molecular species 
of LPA in serum as these fatty acids are in the sn2 position of phospholipids.  
However, the role of two other PLA enzymes also occurred. Group II sPLA2 and 
lipoprotein-associated PLA2 are enzymes implicated in chronic inflammation and 
produce LPC. Varespladib, an inhibitor of the former as well as darapladib, which 
inhibits the latter, reduced atherosclerosis in mice (402). These enzymes, however, seem 
to play a role in the chronic process of plaque building and not in acute thrombotic 
events. 
Furthermore, LPA was not only associated with platelet activation as a product, but 
itself was also assumed to elicit thrombocyte activation. In accordance, human and cat 
platelets are activated by LPA, while that of rodents are not (403, 404). Moreover, 
murine platelets are inhibited by LPA (54). In support of this hypothesis, ATX 
overexpression in adult mice evokes hemorrhages, whereas mice heterozygote for ATX, 




thromboses more often (54). Furthermore, the thrombocytes of 20% of the healthy 
human population failed to respond upon LPA-stimulation (405). Further studies found, 
that LPA-induced platelet aggregation was ADP-dependent, which displayed, that LPA 
itself does not cause thrombocyte activation, but plays a role in the shape-change of 
platelets in an ADP- or other platelet activator-dependent manner (406). In support of 
this, LPA has been shown not to act on Gαi in thrombocytes, which is the initial step in 
their activation (393). LPA-induced shape-change has been described to be Gα12/13-
dependent, through which LPA activates Rho, ROCK, and the actomyosin system on 
the one hand and the LIM-kinase-1 cascade on the other hand (393). As for the 
receptors involved, human platelets express all known LPA GPCRs with LPA4 and 
LPA5 in the highest amount (285, 407, 408). First, only indirect evidence suggested a 
role for either of these receptor, as alkyl-analogues of LPA were more potent than acyl 
ones, a feature typical for LPA5 (393). A further investigation by Kandoga and 
colleagues showed, that knockdown of LPA5, but not that of LPA1-4 or LPA6 inhibited 
LPA-mediated shape-change in human megakaryocytic cell lines (278). As for LPA4, it 
is hypothesized, that it would be responsible for the LPA-mediated inhibition in rodents 
and in that 20% of the human population, whose platelets do not respond to LPA (408). 
There are two studies of human subjects from the same group, which bind LPA 
directly to acute coronary syndrome (ACS), one of the fatal consequences of 
atherosclerosis (409, 410). In the former paper it was reposted, that circulating plasma 
LPA levels increase in patients with ACS compared to patients with stabile angina 
pectoris or angiographically normal coronary arteries (409). In the latter publication, a 
higher LPA level was found at sites in culprit coronary arteries than in the peripheral 
circulation of patient with ACS (410). Although, these experiments exhibit a potential 
biomarker role for LPA in ACS, they are difficult to interpret, because no precautions 
were taken to inhibit in vitro LPA generation during sample handling, and LPA levels in 
healthy subjects were higher than previously reported by others (393). 
The putative role of S1P in atherogenesis was identified early, as plasma S1P is 
largely bound to HDL, a well-known atheroprotective factor. Although S1P has been 
extensively studied in this context, it could not be established as either a pro- or an anti-





In endothelial cells, S1P was found to suppress IL-8 and CCL2. Furthermore, S1P 
inhibited VCAM-1, a key adhesion molecule, mediating monocyte invasion into the 
vessel wall. In contrast, additional studies described enhanced VCAM-1 and E-selectin 
expression upon S1P-treatment. It is noteworthy, that opposite effects occurred upon 
application of different concentrations of S1P. While micromolar concentrations 
increased, nanomolar ones lowered the expression of the aforementioned adhesion 
molecules (411). Early studies reported, that S1P improves endothelial barrier function 
by facilitating adherens junction formation via activation of S1P1 (412). The possible 
role of S1P3 has been proposed, however, this issue is still under debate (412). In 
contrast, S1P2 proved to increase endothelial permeability, acting on Rho-ROCK and 
PTEN (411). Nonetheless, the net effect of S1P on vascular permeability is rather an 
enhancement of its barrier function, as mice deficient in plasma S1P exhibited vascular 
leakage, a feature could be restored by either transfusion of WT type red blood cells or 
application of an S1P1 agonist. Besides, SK1 global KO mice also suffer from vascular 
leakage, however in a less extent (411). Furthermore, barrier-enhancing functions of 
activated protein C proved to be at least partially S1P-dependent, and an S1P1 agonist 
can rescue mice from PAF-evoked general vascular leaking (411). 
Three independent studies investigated the therapeutic potential of FTY720 in 
atherosclerosis, two of which concluded attenuation in plaque-formation in two distinct 
established mouse models of the disease (413, 414) and in a third one, Fingolimod had 
no effect, although evoked hypercholesterinemia (415). The interpretation of these 
studies is however difficult, considering the wide range of effects FTY720 has on S1P 
receptors and producing enzymes, addressed previously in detail. 
Experiments conducted with S1P receptor KO mice, however, contradict with the 
former results. S1P2 KO animals on ApoE KO background showed clearly reduced 
plaque burden, decreased macrophage density and increased VSMC content of the 
plaques. Bone-marrow transplantation studies pointed out, that S1P2 receptor located on 
macrophages are responsible for the aforementioned effect. Absence of S1P3 had no 
direct influence on atherosclerosis, though it alleviated monocyte/macrophage content 
of the lesions (411). 
Finally, S1P also has an ambiguous effect on cytokine production, with S1P1 on the 




As seen from the observations listed above, while LPA actions can be concluded pro-
atherogenic, with LPA1/3 signaling in plaque formation and LPA5 activation in 
thrombocyte shape-change, the role of S1P in atherogenesis is far from being clear, as 
S1P1 signaling seems to be anti-atherogenic, and S1P2 is pro-atherogenic on the other 
hand. 
2.4.5.3. Cardiac functions 
In contrast with LPA, the role of S1P in functions of the heart has been extensively 
studied, hence its effect on this organ should be addressed separated and in more detail 
than that of LPA. S1P influences heart development, highlighted by the fact, that 
cardiomyocyte-specific S1P1 KO mice exhibit ventricular septal defects (416). Besides, 
S1P was found to be involved in ischemia-reperfusion injury, in which it would be a 
protective factor. In a porcine ischemia-reperfusion injury model, treatment with 
FTY720 increased myocardial salvage and reduced adverse post-injury remodeling. 
Furthermore, cardiomyocytes lacking SK1 proved to be more sensitive to hypoxia than 
WT ones, manifested in a greater extent of cell-death. Treatment with exogenous S1P 
could however, increase the survival of KO as well as WT cardiomyocytes. Moreover, 
hearts of SPL KO mice exhibited higher S1P levels and smaller infarct sizes following 
myocardial ischemia (417). 
Multiple studies point to a cross-talk mechanism between S1P1 and β1-adrenergic 
signaling, in which S1P1 agonism counteracts β1-activation, decreasing contractility. At 
first sight, this effect may seem to be deleterious for the heart in a post-ischemic 
condition. The level of circulating catecholamines is increased in this set up though, and 
that would lead to an excessive activation and rapid desensitization of β1 receptors. 
Hence, this opposing effect of S1P can be beneficial under these circumstances. 
Moreover, S1P1 action was reported to be modulated by β3 activation in 
cardiomyocytes, a mechanism of interest, which may have a role in preventing post-
ischemic heart failure (417). 
In addition, S1P1, S1P2, and S1P3 may also contribute to the protection of the heart. 
Although S1P2 and S1P3 KO animals showed similar sizes of infarcts upon ischemia to 





Furthermore, the role of S1P also occurred in the regulation of the hearth rate. 
Studies conducted by Bünemann and colleagues in the mid 90’s revealed that in isolated 
guinea pig atrial myocytes S1P and SPC activate the G protein-coupled inwardly 
rectifying potassium channel in a GPCR-dependent manner, the channel also targeted 
by the M2 ACh receptors upon parasympathetic stimuli. This effect of S1P and SPC is 
mediated by Gαi, as it can be suppressed by PTX. S1P and SPC showed homologue 
desensitization, implicating that the two mediators act on the same receptor, which is a 
distinct one of M2, as carbachol could not desensitize their effect (418, 419). In 
addition, Liliom and colleagues found that guinea pig atrial myocytes express S1P1-3, 
and S1P5, and that SPC has a negative chronotropic effect on perfused guinea pig hearts 
(147). Moreover, bradycardia is a recognized adverse effect of Fingolimod, applied in 
multiple sclerosis. This effect was lacking in mice deficient in S1P3 (420). However, 
data acquired in rats (421) and humans (422) supported a participation of S1P1 in this 
process. 
Lastly, changes in circulating S1P levels were also investigated in coronary artery 
disease and acute myocardial infarction. Reduction in S1P levels were reported in 
humans with acute myocardial infarction (423). The same was observed in case of post-
ischemic heart failure in rodents. The bulk of S1P in plasma, is however, bound to 
HDL, the level of which is also altered in these conditions (417). Algraves and 
colleagues found that circulating S1P, dihydro-S1P and C24:1-ceramide levels in HDL 
were inversely correlated with the incidence of ischemic heart disease (424). 
2.4.5.4. Regulation of the vascular tone 
The initial report on LPA by Tokumura described, that intravenous administration of 
LPA elicited hypertension in rats and guinea pigs but the same molecular species 
proved to be hypotensive in cats and rabbits (4). This hypotensive effect in cats was 
attributed to a decreased cardiac output, which was a result of pulmonary 
vasoconstriction upon platelet aggregation (404). Intravenous application of LPA 
elevated the mean arterial pressure in LPA1 KO, LPA2 KO and LPA1/2 double KO mice 
as well as in LPA4 KO and smooth muscle specific PPARγ KO animals. The same 
effect was also observed in LPA3 KO animals (425). A recent report by Kano and 
colleagues described a hypertensive response upon intravenous LPA application in 




the ROCK inhibitor Y-27632. However, LPA6 KO mice also showed attenuated 
vasoactive responses upon adrenergic stimuli and exhibited abrupt vessel formation 
(295). 
 LPA applied on the extraluminal surface of porcine pial arteries in a cranial window 
set-up elicited a dose-dependent vasoconstriction (426). This effect was Gαi dependent, 
because it could be inhibited by PTX. Because LPA receptors were undiscovered that 
time, the receptor responsible for the effect remained obscure. Furthermore, intrathecal 
application of autologous blood or Endothelin-1, as a model of subarachnoidal 
hemorrhage, raised the concentration of LPA in the cerebrospinal fluid into the 
vasoactive range (427).  
The endothelium and eNOS play key roles in regulation of the vascular tone. LPA 
was shown to activate eNOS and thus elicit NO generation in endothelial cell cultures 
(428-430), however 24 h incubation of porcine coronary endothel cells with LPA 
downregulated the transcription of eNOS (431). In bovine aortic endothelial cell 
(BAEC) culture, LPA-induced eNOS activation was mediated by PI3K (429), 
nonetheless, in an other study, conducted also on BAEC, inhibition of PI3K had no 
effect on eNOS activity (430). These investigations, however, should be treated with 
caution as endothelial cell properties may vary on experimental setup (432, 433). 
Expressional profile of BAEC changes in a great extent under cultured conditions (434). 
A report also pointed out the lack of glycocalyx in cultured HUVECs; however, it 
mediates important physiological interactions (435). Endothelium-dependent flow-
stimulated NO production is a key regulator of the tone of resistance arterioles in 
mammals (436). A recent study reported, that in adipose tissue arterioles of human 
subjects with coronary artery disease, LPA elicits a shift in the mediator of flow-
induced dilation from NO to mitochondria-derived H2O2 in an LPA1-dependent manner 
(437). LPA, on the other hand, was also shown to induce endothelium-dependent 
vasoconstriction if shear stress was present (438).  
The effects of S1P on the vascular tone have been studied broadly. An early report 
described S1P as a constrictor in basilar artery of dogs in a Rho-ROCK-dependent 
manner (439). In vivo, injected into the cysterna magna, S1P elicited a contraction of 
duration lasting for approximately 2 days. Since then, this effect has been confirmed in 




potent only in smaller arteries (cerebral, mesenteric) with moderate (coronary) to no 
effect (aorta, femoralis) in larger ones (440). In mice, the efficacy was in negative 
correlation with size (440). Further, in mice S1P caused S1P3-dependent contraction of 
the basilar artery (441). A study, conducted in human chorionic plate arteries, found, 
that the outcome also depends on the experimental setup (isometric vs. isobar mounting) 
(442). Pharmacological investigations confirmed the S1P-elicited vasoconstriction to be 
S1P3-dependent in basilar and coronary arteries (411, 440). 
Thorough investigations of S1P2 KO mice revealed interesting results though. These 
animals exhibited a decreased vascular tone; however, this had no influence on blood 
pressure. Furthermore, blood flow of the renal and mesenteric areas was elevated with 
consequent smaller vascular resistance. Additionally, responses of the vessels to α-
adrenergic stimuli were also decreased (252). The subjects also showed a more severe 
drop in blood pressure in an anaphylactic test (443). 
Receptor-independent constrictive actions of S1P were also reported (411). Vessels 
deficient in SK1 showed reduced contractile responses to KCl, S1P, or the thromboxane 
receptor agonist U46619 compared to WT, S1P2 KO or S1P3 KO arteries (411). 
Besides, S1P can activate store-operated calcium entry through receptor-dependent and 
independent pathways (444). 
Interestingly, S1P was found to activate eNOS and thus promote NO release in 
rodent aortic rings, which proved to be mediated via S1P3 at least in mice (445, 446). A 
possible contribution of S1P1 also occurred, however the lack of highly selective 
antagonists makes these results disputable (440). On the other hand, S1P elicited eNOS 
activation in COS-7 cells, transfected with eNOS and S1P1 in an S1P1-dependent 
manner (447). Furthermore, S1P elicited eNOS activation in BAEC (448). Moreover, 
VEGF was shown to increase S1P1 expression in aortic endothelial cells, and 
pretreatment of isolated vessels with VEGF enhanced S1P-dependent vasodilation 
(449). In rat mesenteric arterioles, S1P-induced dilatation was inhibited by PTX, and the 
PI3K inhibitor wortmannin. Likewise, S1P can activate eNOS via AMP-activated 
protein kinase. Nonetheless, the S1P1 agonist SEW2871 failed to induce any relaxation 
in basilar, femoral or mesenteric arteries of rats (440). 
In summary, LPA as well as S1P have a multitude of actions in the cardiovascular 




however in both cases, the receptor-dependency is mostly unsure, which require further 




3. Aims of the study 
The brief summary of the last chapter showed that both LPA and S1P play several, 
physiologically significant roles in the cardiovascular system. As for the regulation of 
the vascular tone, a large amount of data is available for both mediators. Constrictor and 
dilator responses have been reported in case of both lysophospholipids. Nonetheless, 
these results and especially the receptor-dependency of the described effects are unclear 
and often inconsequent. 
Accordingly, in the present study we addressed the following questions: 
1. Are there any EDG LPA receptor-mediated vasoactive actions? 
2. If yes, are they endothelium-dependent or independent? 
3. Which receptors and underlying signaling pathways may be involved? 
4. Does the activation of the S1P GPCRs mediate any vasoactive processes? 
5. If yes, are they dependent of the endothelium? 












4. Materials and Methods 
All procedures were carried out according to the guidelines of the Hungarian Law of 
Animal Protection (28/1998) and were approved by the National Scientific Ethical 
Committee on Animal Experimentation (PEI/001/2706-13/2014). 
4.1. Animals 
C57BL/6 and eNOS KO mice were obtained from Charles River Laboratories 
(Isaszeg, Hungary). C57BL/6 mice are referred to as WT in the text and figures. All 
transgenic mouse lines were on C57BL/6 genetic background. Mice deficient in LPA1 
or LPA2 receptors (LPA1 KO and LPA2 KO, respectively) were generated as previously 
described (192, 202, 326, 450). Cyclooxygenase-1 KO (COX1 KO) mice were from Dr. 
Ingvar Bjarnason (Department of Medicine, Guy’s, King’s College, and St. Thomas' 
School of Medical Education, London, UK). Thromboxane prostanoid receptor-
deficient (TP KO) mice were kindly provided by Dr. Shuh Narumiya (Kyoto 
University, Kyoto, Japan). The smooth muscle-specific Gαq/11 and Gα12/13 deficient 
mice (Gαq/11 KO and Gα12/13 KO respectively) and their respective controls (Gαq/11 
CTRL and Gα12/13 CTRL), were generated as described (451). Mice deficient in S1P2- 
and S1P3 receptors (S1P2 KO, S1P3 KO) and their controls were kindly provided by Dr. 
Richard L. Proia (National Institute of Diabetes and Digestive and Kidney Disease, 
NIH, Bethesda, USA). In experiments performed with LPA1 KO, LPA2 KO or COX1 
KO mice, wild-type animals from the same strain served as controls and are referred to 
as LPA1 CTRL, LPA2 CTRL and COX1 CTRL, respectively. Because the TP mice have 
been maintained in our animal facility with KO x KO mating, WT C57BL/6 mice 
served as controls (TP CTRL). PTX was administered intraperitoneally in some of the 
animals for 5 days prior to the experiments in a dose of 50 μg/kg body weight in order 
to inhibit Gi proteins (452, 453). 
4.2. Preparation of Vessels 
Adult male animals were perfused transcardially with 10 mL heparinized (10 IU/mL) 
Krebs solution under deep ether anesthesia as described previously (454). The aorta was 
removed and cleaned of fat and connective tissue under a dissection microscope (M3Z, 




following composition (mM): 119 NaCl, 4.7 KCl, 1.2 KH2PO4, 2.5 CaCl2·2 H2O, 1.2 
MgSO4·7 H2O, 20 NaHCO3, 0.03 EDTA, and 10 glucose at room temperature and pH 
7.4. Abdominal and thoracic aortae were cut into ~3 mm-long segments and mounted 
on stainless steel vessel holders (200 µm in diameter) in a myograph (610 M multiwire 
myograph system; Danish Myo Technology A/S; Aarhus, Denmark). In certain 
experiments special care was taken to preserve the endothelium of the segments, in all 
other cases the endothelium was removed intentionally by gently rotating the segments 
on the holder pins and mechanical ablation with surgical thread. Integrity or absence of 
the endothelium was confirmed by the presence or lack of ACh-induced vasorelaxation 
respectively. Thoracic aortae were also cut into segments and subjected, with the 
endothelium preserved, to thromboxane B2 ELISA as described below in detail. 
4.3. Myography 
Chambers of the myographs were filled with 6 mL gassed (95% O2–5% CO2) Krebs 
solution. The vessels were allowed a 30-min resting period, during which the bath 
solution was warmed up to 37 
o
C and the passive tension was adjusted to 10 mN in case 
of abdominal and to 15 mN in case of thoracic segments, which was determined to be 
optional in a previous study (454). Subsequently, the tissues were exposed to 124 mM 
K
+




) for 1 min, followed 
by several washes with normal Krebs solution. A contraction evoked by 10 μM 
phenylephrine (PE) followed by administration of 0.1 μM ACh served as a test of the 
reactivity of the smooth muscle and the endothelium, respectively. After repeated 
washing, during which the vascular tension returned to the resting level, the segments 
were exposed to 124 mM K
+
 Krebs solution for 3 min in order to elicit a reference 
contraction. Subsequently after a 30-min resting period, increasing concentrations of PE 
(0.1 nM to 10 μM) and ACh (1 nM to 10 μM) were administered to determine the 
reactivity of the vessel and to verify the integrity or the proper denudation of the 
endothelium. We proceeded with a 30-min resting period. Thereafter, we followed three 
distinct protocols, depending on the aim and setup of the given experiment.  
4.3.1. Protocol for testing vasoactive effects in precontracted vessels 
Thoracic vessels were precontracted to 70–90% of the reference contraction by an 




the LPA1-3 agonist VPC31143 (455) in a concentration of 10 μM or that of S1P in 5 μM 
was determined in vessels of different genetic background. Vasoconstrictions were 
normalized to the reference contraction induced by 124 mM K
+
, whereas 
vasorelaxations were expressed as percentage of the precontraction produced by PE 
4.3.2. Protocol for testing vasoactive effects on resting tone  
In this type of protocols, the vessels were exposed to either 10 μM VPC31143 or 
different concentrations of the LPA3 agonist T13 (456) or 5 μM S1P at the resting tone. 
In some experiments, the LPA1&3 receptor antagonist Ki16425 (457) or the selective 
LPA3 antagonist diacylglycerol pyrophosphate (DGPP) (458) was applied to the bath 
chambers at a concentration of 10 μM, 30 min prior to the administration of VPC31143. 




4.3.3. Protocol for testing the long-term vasoactive effects of S1P 
In these experiments, we investigated the potentiating effect of S1P on an α1 agonist-
induced contraction in thoracic vessels. Vasoconstrictions were elicited in every 20 
minutes by repeated administration of PE. Mean of the first three contractions served as 
reference and was considered as 100%. After the third administration of PE, we 
incubated the vessel with either S1P in a concentration of 5 μM, or its vehicle 0.3 N 
sodium hydroxide (NaOH). Subsequently, PE was applied every 20 minutes for three 
hours after the incubation. Vasoconstrictions are expressed as percentage of the mean of 
the three contractions, evoked before the incubation.  
4.4. Quantification of Vascular Thromboxane A2 Release 
Thoracic aortae were cut into 5 segments and allowed a 2-h resting period. In some 
of the experiments, 3 μg/mL PTX was applied for 2 h in order to inhibit Gi (459). 
Thereafter, the vessels were incubated in 200 μL Krebs solution at 37
o
C for 2 min to 
obtain a baseline level of TXA2 release. After the incubation, the supernatant was 
replaced with 200 μL of Krebs solution containing 10 μM VPC31143 and incubated for 
2 min. Supernatants of the resting and the VPC31143-stimulated vessels were snap-
frozen and stored at -80
o
C until the measurement of thromboxane levels. Concentrations 




were determined using a TXB2 EIA kit, purchased from Cayman Chemical Co. (Ann 
Arbor, MI, USA; Cat. No.: 501020). TXB2 production was calculated as pg/min. 
Vessels with a baseline production of TXB2 higher than 20 pg/min were considered pre-
activated and were excluded from the experiment. 
4.5. Expression Analysis of LPA and S1P Receptors in VSM 
Endothelium-denuded thoracic and abdominal aortae were isolated, and the 
adventitia of the vessels was carefully removed under a dissection microscope. 
Thereafter the vessels were fast-frozen and stored at -80
o
C until PCR analysis. RNA 
was isolated from VSM with the RNeasy Micro kit (Qiagen, Valencia, CA, USA; Cat. 
No. 74004), and RNA concentration and quality were assessed with Nanodrop (Thermo 
Fischer Scientific; Waltham, MA, USA). Up to 500 ng total RNA was converted to 
cDNA using a SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen; Carlsbad, CA, 
USA; Cat. No.: 11754050). 
Assessment of mRNA expression was performed by quantitative real-time PCR using 
cDNA corresponding to 20 ng RNA template. PCR reactions were carried out in 
triplicate with 300 nmol of each primer in a final volume of 25 μL of 2 x Maxima 
SYBR Green/ROX qPCR master mix (Thermo Fischer Scientific; Cat. No. K0223). 
Amplification was performed after one initial step of 10 min at 95°C for 40 cycles at 
94°C /15 s and 60°C /60 s with a StepOnePlus real-time PCR system (Applied 
Biosystems; Carlsbad, CA, USA). Relative gene expression of each mRNA to GAPDH 
was determined using the dCt method. The primer sequences of LPA GPCR are listed in 
Table 1. The primers used for expression analysis of S1P receptors were manufacturer 
designed TaqMan probes (Thermo Fischer Scientific).  
Table 1. Primers used for quantitative real-time PCR, GAPDH: Glyceraldehyde 3-phosphate 
















LPA (18:1) and VPC31143 were purchased from Avanti Polar Lipids (Alabaster, 
AL, USA) and dissolved in saline immediately before administration. DGPP was 
purchased from Avanti Polar Lipids and dissolved in methanol. Ki16425 was purchased 
from Cayman and dissolved in DMSO to make a 100-fold concentrated stock solution. 
In these experiments, vehicle treatment served as control. PTX was purchased from List 
Biological Laboratories, Inc. (Campbell, CA, USA) and dissolved in glycerol. T13 was 
synthesized as described previously (456) and was dissolved in PBS containing 0.1 % 
fatty acid free bovine serum albumin. Sphingosine 1-phosphate was purchased from 
Cayman Chemical Company (Ann Arbor, Michigan, USA) and dissolved in 0.3 N 
NaOH before administration. All other drugs and chemicals used in the present study 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). In myography experiments, 
all concentrations are expressed as the final concentration in the organ bath. 
4.7. Data Analysis 
An MP100 system and AcqKnowledge 3.72 software from Biopac System Inc. (Goleta, 
CA, USA) were used to record and analyze changes in the vascular tone. All data are 
presented as mean ± SE, and n indicates either the number of vessels tested in 
myography experiments or the number of animals tested in the case of TXB2 EIA or 
qPCR. Statistical analysis was performed using the GraphPad Prism software v.6.07 
from GraphPad Software Inc. (La Jolla, CA, USA). Student’s unpaired t test was 
applied when comparing two variables, whereas all other comparisons between the 
different experimental groups were made by ANOVA followed by either Tukey’s or 







5.1. Activation of EDG-like LPA receptors induce endothelium-dependent and -
independent changes of the vascular tension 
In order to evaluate the potential vascular effects of LPA EDG-like GPCRs, the 
LPA1-3 agonist VPC31143 was administered to WT thoracic aortic segments after PE-
induced precontraction. VPC31143 elicited a marked vasorelaxation (Figures 8A and 
9A). Dose-response relationship of this effect is shown in Figure 9B. The agonist-
induced vasorelaxation has an EC50 of 15 nM and an Emax of 51.9% expressed as 
percentage of the precontraction. 
 
Figure 8. Effect of VPC31143 on the tone of precontracted thoracic aortae. Representative recordings of 
vessels prepared from wild type (WT) mice with intact (A) or denuded (B) endothelium as well as vessels 
from endothelial nitric oxide synthase (eNOS) KO (C) and cyclooxygenase-1 (COX1) KO (D) mice. 
VPC31143 was applied at 10 μM after phenylephrine (PE)-induced contraction reached a stable plateau. 
Horizontal and vertical bars indicate 5 min and 5 mN, respectively. PE and VPC denote the application of 
phenylephrine and VPC31143 respectively, while W stands for washing of the organ chamber with fresh 
Krebs solution.  
 
In order to analyze the mechanism of VPC31143-evoked relaxation the possible role 




vessels, mechanically denuded of endothelium, in which the VPC31143-elicited 
relaxation was not only abolished but was converted to vasoconstriction (Figure 8B) 
indicating a major role of endothelium-derived vasoactive mediators in the vasoactive 
effect of VPC31143. In order to identify the mediator(s) involved, vessels of either 
COX1 KO or eNOS KO mice were tested. Whereas the absence of COX1 did not alter 
the dilator effect of VPC31143 (Figure 8D), the lack of eNOS, similarly to that of the 
endothelium, prevented the VPC31143-elicited relaxation and turned it to contraction 
(Figure 8C). Taken together, these results indicate that the vasorelaxant effect of EDG-
like LPA receptor activation is mediated by endothelial NO whereas COX1-derived 
prostanoid mediators are not involved (Figure 9A). 
 
Figure 9. A) Endothelium-derived NO mediates the vasorelaxation induced by VPC31143. Effects of 10 
μM VPC31143 in wild type (WT) vessels with intact (open bar) or denuded endothelium (solid bar) as 
well as in vessels of endothelial nitric oxide synthase (eNOS) KO (dark grey bar) and cyclooxygenase-1 
(COX1) KO (light gray bar) mice. Absence of endothelium or eNOS but not that of COX1 abolished 
VPC31143 induced vasorelaxation. 
****
P<0.0001 vs. WT with intact endothelium; One-way ANOVA 
with Tukey’s post hoc test; n = 11-28 B) Dose-response relationship of vasorelaxation induced by 
VPC31143 in WT thoracic aortic vessels with intact endothelium. Each dose has been tested in 
independent aortic segments in order to avoid receptor desensitization. Emax and EC50 values are 51.9% 
and 15 nM, respectively; n=7-29. 
 
In the next phase of our study, we sought an in-depth analysis of the VPC31143-
evoked vasoconstriction. In order to analyze the potential regional differences between 
the different parts of the aorta the agonist was applied to WT thoracic and abdominal 
aortic segments (TA and AA, respectively) at resting tension. In vessels with intact 
endothelium VPC31143 in a dose of 10 µM elicited moderate vasoconstriction 
compared to the reference contraction induced by 124 mM K
+






Figure 10. Representative recordings depicting the effect of VPC31143 in murine thoracic (TA) and 
abdominal aorta (AA) with intact endothelium (A and C respectively) and in TA and AA after 
endothelium-denudation (B and D, respectively). VPC denotes the application of VPC31143, while W 
stands for washing of the organ chamber with fresh Krebs solution. 
However, removal of the endothelium unmasked the constrictor effect of VPC31143 
resulting in an approximately three-fold increase in the AA (Figures 10B, 10D and 
11A). Figures 11B shows the dose-response relationship of the contractile effect of 
VPC31143 in AA. The vasoconstriction has an EC50 of 4.1 µM and an Emax of 87.4% as 
compared to the reference contraction. 
 
Figure 11. A) Removal of the endothelium enhances the VPC31143-elicited vasoconstriction in the 
abdominal aorta (AA). Effect of 10 μM VPC31143 in wild type (WT) thoracic aorta (TA) (solid bars) and 
AA (open bars) 
**
P<0.01 vs. TA with denuded endothelium; 
###
P<0.001 vs. AA with intact endothelium; 




elicited by VPC31143 in WT AA vessels after the removal of the endothelium. Emax and EC50 values are 
87.4% and 4.1 μM, respectively; n=4-30.  
5.2. Identification of the LPA receptor(s) mediating VPC31143-induced 
vasoconstriction 
Since removal of the endothelium augmented the vasoconstrictor effect of 
VPC31143, our attention turned to LPA GPCRs expressed in the vascular smooth 
muscle (VSM). First, the gene expression profile of LPA receptors was determined in 
isolated tunica media of the murine TA and AA. LPA1, LPA2, LPA4, and LPA6 mRNA 
were most abundantly detectable, with a slightly higher expression of LPA4 and LPA6 
in the AA as compared to the TA (Figure 12). LPA3 transcripts had the lowest 
abundance, nonetheless they found to be expressed in a higher amount in TA than AA. 
Taken together, these results identified LPA1 and LPA2 as likely candidates for 
mediating EDG-like LPA receptor related vasoconstriction. 
 
 
Figure 12. Expression profile of LPA receptors in freshly isolated tunica media of wild type murine 
thoracic (TA) and abdominal aortic (AA) segments, determined by quantitative PCR. Murine aortic 
vascular smooth muscle cells predominantly express LPA1, LPA2, LPA4, and LPA6. LPA4 and LPA6 
proved to be more abundant in the AA whereas LPA3, the least abundant subtype, showed higher 
expression in the TA. 
*
P<0.05 vs. TA; Student’s unpaired t test; n=3-9. GAPDH: Glyceraldehyde 3-
phosphate dehydrogenase 
 
Thereafter, we implemented pharmacological and genetic methodologies to 
determine the LPA receptor responsible for the vasoconstrictor effect (Figures 13 and 
14). Whereas the LPA1/3 antagonist Ki16425 revoked the 10µM VPC31143-elicited 
vasoconstriction, the selective LPA3 antagonist DGPP failed to influence it as compared 




failed to contract upon VPC31143 application, while the vessels of LPA2 KO animals 
showed similar responses to those of WT, indicating that the vasoconstriction is 
mediated by LPA1 (Figure 13).  
 
Figure 13. LPA1 receptors mediate VPC31143-elicited vasoconstriction. Ki16425, an LPA1/3 antagonist, 
and the lack of LPA1 but not that of LPA2 receptors nor the selective LPA3 antagonist DGPP abolish 
VPC31143-evoked contraction. Segments of C57Bl/6, LPA1 control (CTRL), and LPA2 CTRL exhibited 
identical responses and are therefore pooled and referred to as WT in the figure. Both Ki16425 and DGPP 
were applied at 10 μM for 30 min before the administration of VPC31143. Vehicle-treated control vessels 
were exposed to 1% Dimethyl sulfoxide (DMSO) or methanol (MeOH). 
****
P<0.0001 vs. WT; 
##
P<0.01 
v. WT with DMSO treatment; One-way ANOVA with Tukey’s post hoc test; n=5-23. 
 
To obtain a more detailed evaluation of the possible involvement of LPA3 in the 
vasoconstrictor response, the vasoactive effects of T13 were investigated, which had 
been implied to activate LPA3 selectively and with high efficiency at 10 nM, however at 
higher concentrations, it stimulates other LPA GPCRs as well (456). T13, applied in 10 
nM concentration, failed to induce vasoconstriction in AA segments of LPA1 CTRL 
animals, however at higher concentrations a dose-dependent contractile response 
developed (Figure 14). This effect was absent in vessels isolated from LPA1 KO 
animals, which is consistent with our hypothesis, that the vasoconstrictor response is 







Figure 14. LPA3 has no role in VPC31143-mediated contraction. The selective LPA3 agonist T13 failed 
to evoke vasoconstriction in LPA1 control (CTRL) vessels at 10 nM where it selectively activates LPA3. 
The application of higher concentrations of T13, which are reported to stimulate LPA1, resulted in dose-









P<0.0001 vs. 10 nm LPA1 CTRL; Two-way ANOVA with Tukey’s post hoc 
test; n= 16-22. 
 
5.3. Identification of the signal transduction pathways of LPA1-mediated 
vasoconstriction 
LPA signaling has been implicated to interact with the prostanoid system. COX1-
mediated effects of LPA (460) and the fact that LPA-evoked contractions of the 
longitudinal smooth muscle layer of guinea-pig ileum were shown to be indomethacin-
sensitive (461), raised our hypothesis, that TXA2, a potent vasoconstrictor (462), might 
have a role in the contractile effect mediated by LPA1. In order to investigate this 
possibility, vessels of WT, COX1 KO and TP KO mice were exposed to 10 µM 
VPC31143. The absence COX1 and TP markedly decreased the agonist-induced 
contractions (Fig. 15), implying that COX1-derived TXA2 could be the mediator, that 







Figure 15. Prostanoids are involved in VPC31143-mediated contraction. The vasoconstriction evoked by 
VPC31143 at 10 μM was markedly reduced in the abdominal aortic segments of cyclooxygenase-1 
(COX1) KO and Thromboxane prostanoid receptor (TP) KO mice as compared with control (CTRL) 
animals. 
****
P<0.0001 vs. the corresponding CTRL; One-way ANOVA with Tukey’s post hoc test; n=8-
23. 
 
To verify the presence of the constrictor agent TXA2, levels of TXB2, a metabolite of 
TXA2 with a longer life span, were measured from the supernatants of vessels exposed 
to VPC31143 for 2 min (Figures 16 and 17). VPC31143 treatment enhanced the TXB2 
production of WT specimens more than two-fold, which was also the situation in case 
of LPA2 KO aortae. However, the agonist failed to alter the amount of TXB2, released 
from LPA1 KO vessels (Figure 16).  
 
Figure 16. LPA1 is responsible for VPC31143 mediated vascular Thromboxane A2 (TXA2) release. The 
lack of LPA1 but not that of LPA2 abolished the VPC31143-elicited increase in TXA2 production in TA 
segments. LPA1- and LPA2 control mice showed identical responses and are therefore pooled and referred 




P<0.0001 vs. before VPC; 
####
P<0.0001 vs. control after VPC; Two-way 





Aortae of COX1 KO mice showed a diminished basal rate of TXB2 production, 
which remained unaltered upon VPC31143 application. Nonetheless, absence of the TP 
receptors had no such effect on either resting or stimulated release of TXB2 (Figure 17). 
The above mentioned results are consistent with our hypothesis of LPA1-mediated 
COX1 activation and TXA2 production, leading to TP activation and consequent 
contraction of VSM. 
 
 
Figure 17. VPC31143 treatment leads to increased Thromboxane A2 (TXA2) release in cyclooxygenase 
(COX1) control (CTRL) thoracic aortic segments, whereas COX1 KO vessels exhibited diminished basal 
rate of TXA2 production that did not increase upon VPC31143 administration. On the contrary, basal and 
VPC31143-stimulated TXA2 release from thromboxane prostanoid receptor (TP) KO vessels showed no 








P<0.0001 vs. corresponding COX1 CTRL; Two-way ANOVA with Bonferroni’s post hoc test, n=3-7. 
 
As LPA1 is often coupled to Gαi/o (66), and Gαi/o may activate PLA2 and TXA2 
production (463-465), we sought evidence of its possible role in LPA1-mediated 
vasoconstriction.  In consistence with our hypothesis, PTX pretreatment of WT vessels 
abolished the VPC31143-induced increase in TXB2 production (Figure 18A). Moreover, 
aortic segments of PTX-pretreated WT animals showed diminished vasoconstriction 





Figure 18. Gαi mediates VPC31143-mediated thromboxane A2 (TXA2) production and vasoconstriction. 
A) Pertussis toxin (PTX) pretreatment abolished VPC31143-induced elevation in TXA2 production in 
wild type vessels. 
**
P<0.01 vs. before VPC; 
####
P<0.0001 vs. control after VPC; Two-way ANOVA with 
Bonferroni’s post hoc test; n=5-8. B) PTX treatment markedly decreased VPC31143-elicited contraction 
in wild type vessels. 
***
P<0.001 vs. control; Student’s unpaired t test; n=14-19. 
 
We also investigated, if the well-established regulators of smooth muscle 
contraction, Gαq/11, and Gα12/13, could play a role in the VPC31143-induced 
vasoconstriction. The smooth muscle-specific absence of Gαq/11 (Figure 19A) as well as 
that of Gα12/13 (Figure 19B) decreased the contraction, evoked by 10 μM VPC31143, 
however both failed to completely abolish it. 
 
 
Figure 19. Involvement of Gαq/11 and Gα12/13 in VPC31143-induced vasoconstriction. A) Vessels of 
smooth muscle-specific Gαq/11 KO mice showed diminished contraction upon VPC31143-administration 
as compared with control (CTRL) segments. 
****
P<0.0001 vs. CTRL; Student’s unpaired t test; n=48-50. 
B) The lack of Gα12/13 in the smooth muscle caused a reduction in VPC31143-evoked vasoconstriction as 
compared to CTRL vessels. 
**





5.4. Vasoactive effects of S1P depend on the presence of other constrictors 
In the next part of our experiments, we focused on the vasoactive effects of the other 
thoroughly investigated lipid mediator, S1P. S1P, administered on the basal tone, had 
negligible effect in either thoracic or abdominal aortic segments of WT animals (Figures 
20A, 20B and 21). Removal of the endothelium did not influence this minor effect 
significantly (Figures 20C, 20D and 21). Nonetheless, after PE-induced precontraction 
of endothelium-denuded WT vessels S1P elicited a marked vasoconstriction (Figures 
20E, 20F and 21). Although, S1P applied alone failed to significantly influence the 
basal tone, in presence of an other constrictor, elicited vasoconstriction. Considering the 
fact, that under physiological conditions, several mediators, (e.g. constrictors, dilators) 
are present in the circulation and actively regulate the tension of the vessels, the above-
mentioned effect could play major roles in cardiovascular regulation in vivo. 
 
Figure 20. Effect of S1P applied either at the basal tone or after precontraction. Representative recordings 
of thoracic (A, C and E) or abdominal aortic segments (B, D and F) prepared from wild type mice with 
intact (A, B) or denuded (C-F) endothelium. S1P was applied at 5 μM either at the basal tone (A-D) or 
after phenylephrine (PE)-induced contraction reached a stable plateau (E and F). Horizontal and vertical 
bars indicate 2.5 min and 2.5 mN respectively. S1P and PE denote the application of the respective 
agents, while W stands for washing of the organ chamber with fresh Krebs solution. 
 
In recognition of the imperceptible effect of S1P, applied solely, we investigated if 
this mediator influences the contractile effect of other constrictors. For this purpose, 
vasoconstrictions elicited by the α1 adrenergic receptor agonist PE at 100 nM in WT 
endothelium-intact TAs were investigated and recorded before and after the 






Figure 21. S1P applied at 10μM at the basal tone had negligible effect on the vascular tone in case of 
intact as well as denuded endothelium. However, after precontraction S1P elicited a pronounced 
vasoconstriction. 
****
P<0.0001 vs. intact endothelium, basal tone of the corresponding type of vessel; 
Two-way ANOVA with Tukey’s post hoc test; n=4-6. 
 
 
Figure 22. The effect of S1P on the constrictor effect of the α1 agonist phenylephrine (PE). 
Representative recordings show, whilst incubation with S1P for 20 min significantly enhanced PE-
induced contraction, the vehicle sodium hydroxide (NaOH) failed to do so. The effect was present even 
180 min after the incubation. PE was applied three times before the incubation and the mean of these 
contractions was considered 100% and served as reference for the evaluation of later effects. S1P and PE 
were applied at 5 μM and 0.1 μM respectively. 
Incubation with 5 µM S1P for 20 min, increased PE-mediated contractions almost 




after the incubation (Figures 22 and 23). In contrast, 0.3 N NaOH, the vehicle of S1P, 
had no effect on PE-elicited vasoconstrictions (Figures 22 and 23). 
 
 
Figure 23. Incubation with S1P for 20 min markedly enhanced phenylephrine (PE)-mediated 
contractions, whereas the vehicle sodium hydroxide (NaOH) had no effect on it. The potentiation lasted at 





vs. 0 min; Two-way ANOVA with Tukey’s post hoc test; n=15-18. 
 
5.5. Identification of the S1P receptors, mediating the potentiating effect of S1P 
Thereafter, we aimed to identify the S1P receptor responsible for the S1P-mediated 
augmentation of PE-induced contractions. For this purpose, we first determined the 
expression profile of S1P GPCRs in VSM of the murine thoracic aorta. In WT 
specimens, mRNAs of S1P1, S1P2, S1P3, and S1P4 were detectable, with S1P1 as the 





Figure 24. Expression profile of S1P receptors in freshly isolated tunica media of wild type murine 
thoracic aorta, determined by quantitative PCR. Murine thoracic aortic vascular smooth muscle cells 
predominantly express S1P1, S1P2, S1P3, and S1P4. S1P1 showed the highest abundance, whereas S1P5 
was barely detectable in our specimens. 
 
In the next phase, we applied a genetic approach, thus we tested vessels prepared 
from S1P2 KO and S1P3 KO mice two of the GPCRs which were detectable in the 
isolated tunica media of murine thoracic aorta. In segments of S1P3 KO animals, the 
S1P-induced potentiation was not different from that observed in WT vessels. 
Nevertheless, aortae of S1P2 KO mice failed to develop the above mentioned 
phenomenon after 20 min incubation with S1P, highlighting the role of this receptor in 
S1P-induced potentiation of PE-mediated contractions (Figures 25). 
 
Figure 25. S1P2 is responsible for the potentiating effect of S1P. The lack of S1P2 but not that of S1P3 
abolished the S1P-induced increase in phenylephrine (PE)-mediated vasoconstrictions. S1P and PE were 
applied at 5 μM and 0.1 μM respectively. 
*
P<0.05 vs. 0 min; 
#
P<0.05 vs. wild type (WT); Two-way 





The EDG family of GPCRs contains three of the six confirmed LPA GPCRs (LPA1-
3) and all of the known S1P receptors (S1P1-5). In the present study, we investigated 
their roles in the regulation of the vascular tone with pharmacological and genetic 
approaches. 
6.1. Role of LPA receptors in the regulation of the vascular tone 
In our studies, activation of the EDG-like LPA receptors had ambiguous effects in 
the murine aorta. In precontracted intact vessels, the LPA1-3 agonist VPC31143 elicited 
vasorelaxation in an endothelium- and eNOS-dependent manner, moreover, we could 
rule out the possible role of dilator prostaglandins. Interestingly, mechanical removal of 
the endothelium did not only abolish the dilator effect, but turned it to vasoconstriction. 
We presented first, that this contraction is mediated by LPA1 receptors. The absence of 
vasoconstriction in LPA1 KO mice, the inhibitory impact of the LPA1/3 antagonist 
Ki16425 but not of the LPA3 inhibitor DGPP or the lack of LPA2 receptors emphasized 
the role of LPA1 in this process. Furthermore, our former study conducted with the 
natural ligand LPA concluded, that LPA1 is also responsible for the eNOS-dependent 
vasodilation via activation of PLC enzymes (466). 
Vasoactive actions of the naturally occurring agonist LPA were described early in 
the initial reports of Tokumura and colleagues. The effect however, seemed species-
dependent, as in vivo administration of LPA elicited hypertension in rats and guinea 
pigs, whereas hypotension in cats and rabbits (4). Schumacher and colleagues made 
clear, that the hypotensive effect in cats was a result of excessive pulmonary 
vasoconstriction upon platelet aggregation and a consequent drop of cardiac output 
(404). A recent report of Kano and colleagues showed that intravenous application of 
LPA elicited a hypertensive response in anesthetized mice in an LPA4- and Rho-ROCK-
dependent manner (295). These in vivo studies were certainly unable to differentiate the 
role of VSM and endothelium in mediating the responses. It is noteworthy, that LPA 
had an enhanced pressor impact in spontaneously hypertensive rats compared with 
Wistar-Kyoto rats (467), which implies an increased effect in case of dysfunctional 
endothelium. Studies conducted by Tigyi and colleagues in the 90’s described an LPA-




consistent with ours, because in the cranial window setup they used LPA was applied to 
the extraluminal surface of pial vessels, in which case the mediator reaches the VSM 
primarily.  
Our quantitative PCR results, obtained from freshly isolated murine thoracic and 
abdominal aortic VSMC, showed a rank order of LPA receptors subtype transcripts as 
6>4>1≥2>5>3. Our former expression analysis in murine aortic endothelial cells also 
confirmed the expression of LPA1-5 as well as ATX (466). Others showed that LPA6 is 
expressed in human pulmonary arterial- and microvascular endothelial cells (469). 
These observations indicate that LPA may be involved in both endothelium-dependent 
and –independent regulation of the vascular tone. 
Although LPA1 was first described in the developing brain (9), since that time it has 
been implicated in a multitude of physiological and pathological processes as described 
in detail in the introduction of the present thesis. Cardiovascular functions can be found 
among these roles, which are highlighted by the fact, that 2.5% of LPA1 KO mice 
exhibit frontal hematomas (192). Moreover, LPA1 has a role on atherogenesis and 
platelet activation; this latter action is however disputed (470). 
By seeking to clarify the signal transduction, downstream of LPA1 in the constrictor 
effect, we hypothesized the possible involvement of the constrictor prostanoid TXA2. 
Our results are in support of this hypothesis, as we found, that the application of the 
EDG-agonist VPC31143 elicited increased TXA2 production in isolated vessels, in an 
LPA1- and COX1- but not LPA2- dependent manner. Besides, VPC31143-evoked 
contractions were alleviated in vessels of mice deficient in either COX1 or TP, which is 
in favor of this mechanism, in which the LPA1-dependent activation of COX1 leads to 
the release of TXA2. Moreover, pretreatment with PTX abolished TXA2 generation as 
well as vasoconstriction induced by VPC31143, implying the role of Gi in COX1 
activation. Our further results indicate the involvement of Gαq/11 and Gα12/13 in the 
process. Because the treatment with PTX abolished the VPC31143-elicited elevation in 
TXA2 production, we conclude that LPA1 agonism leads to COX1 activation via Gi and 
not Gαq/11 or Gα12/13. Both Gαq/11 and Gα12/13 were however associated with TP 
signaling (471). Therefore, we hypothesize that Gαq/11 and Gα12/13 are downstream of 
TP in this mechanism. Although, it must be taken into consideration, that on one hand, 




on the other hand, LPA1 was found to be linked to PLC in our former study (466), 
which is associated with Gαq/11. In conclusion, the possibility of a direct link between 
LPA1 and these G proteins cannot be ruled out, which would result in an LPA1-
mediated direct VSMC contraction. This signaling may participate in our system, 
however, considering the remaining contraction in the absence of COX1, TP, or after 
PTX pretreatment, COX1-dependent TXA2 production seems to be dominant in this 
process. 
Interaction of the LPA and the COX/TXA2 pathway has been already described, 
however only in a shear stress-dependent context. Ohata and colleagues reported, that 
LPA stimulate Ca
2+
-influx under shear stress in BAEC and murine aortic endothelial 
cells via mechanosensitive cation channels (472, 473). Furthermore, LPA elicited 
increased PE-induced vasoconstriction and alleviated ACh-evoked relaxation in rat 
mesenteric arteries in the presence of shear stress in an endothelium-dependent manner, 
which was abolished by the non-selective COX inhibitor indomethacin and the TP 
antagonist SQ29548 (474). Moreover, LPA caused elevation of intracellular Ca
2+
-
concentration in VSMCs and contraction of the murine aorta in an endothelial shear 
stress-dependent way. This latter effect could be prevented by application of the COX 
blocker aspirin, the TXA2-synthase inhibitor OKY-046, or the TP antagonist SQ29548 
(438). 
Even though the effects discussed above show similarities with our results, it should 
be emphasized, that in those cases, the process was endothelium- and shear stress-
dependent, whereas our experiments have been performed in vessels denuded of 
endothelium and in absence of shear stress, which indicate a completely different 
mechanism of action. It is noteworthy however, that under pathological conditions, 
which are associated with endothelial damage, e.g. hypertension, the amount of shear 
stress also increases. In such cases, the two mechanisms could be present together. In 
this scenario, LPA would induce TXA2 release from the endothelium or VSMCs, 
leading to vasoconstriction. Upon reduced vascular diameter, shear stress and 
endothelial damage may escalate further, establishing a vicious cycle. 
Further literary data available on the potential interaction of LPA- and prostanoid 
signaling are scant and controversial. LPA-induced contraction in guinea pig ileum was 




inhibition of COX signaling had no effect on LPA-induced contraction of the rat colon 
(475). Ohata et al. described that LPA enhances Ca
2+
-influx upon mechanical 
stimulation in cultured smooth muscle cells, a similar process they reported earlier in 
endothelial cells, however this study did not investigate the possible contribution of 
prostanoids (476, 477). Besides, LPA regulated COX2 expression in the uterus, this 
effect was mediated by LPA3 though, and resulted in production of prostaglandins E2 
and I2 (226). Our findings however imply a direct link between the LPA and 
thromboxane signaling, as activation of the LPA1 receptors on VSMC elicits TXA2 
production and consequently induces a vasoconstriction. 
The results presented here indicate an ambiguous effect upon activation of EDG-like 
LPA GPCRs in the vasculature. To evaluate the potential pathophysiological relevance 
of this process, it must be considered that the production of the natural ligand LPA is 
linked to activation of the thrombocytes. In this context, upon vascular injury, where 
platelets activate and interact directly with VSMCs, the LPA produced locally activates 
LPA1 on VSMCs that leads to TXA2 release via Gi and COX1. TXA2 on one hand 
constricts VSM, on the other hand acts on its receptor on platelets, eliciting further 
activation and aggregation. This interaction between the LPA-LPA1 and the TXA2-TP 
signaling may initiate a vicious circle, in which production of LPA leads to further 
production of TXA2, which in return promotes further LPA release/production from 
platelets, and the elevated levels of these mediators promote thrombus growth and 
sustained vasoconstriction. If the thrombus reaches an intact part of the vessel wall, 
covered by functional endothelium, activation of the endothelial EDG-like LPA 
receptors occurs. In this case, NO-production will follow upon LPA GPCR-dependent 
activation of eNOS as our results illustrate. The NO released prevents further platelet 
activation and acting on VSM elicits vasorelaxation. Our former study revealed a role of 











Figure 26. Integrated hypothesis of LPA1-mediated vasoactive effects in intact vessels versus damaged 
endothelium. Under physiological conditions LPA stimulates endothelial nitric oxide production in an 
LPA1/phospholipase C-dependent manner (466), resulting in vasorelaxation and inhibition of platelets. In 
absence of the endothelium, however, platelet activation initiates LPA production, which in turn acts on 
LPA1 in vascular smooth muscle cells and induces thromboxane A2 (TXA2) production. TXA2 on one 
hand elicits contraction via the activation of the thromboxane prostanoid receptor (TP) in VSMC, and on 
the other hand promotes further platelet activation acting on TP in platelets. TP-mediated activation of 
platelets results in additional LPA production. This mechanism represents a potential positive feed-back 
loop in which platelet activation promotes contraction and further platelet activation via a vicious circle 
involving LPA/LPA1 and TXA2/TP receptors resulting in a pathophysiological vasoconstriction or even 
vasospasm. ATX: Autotaxin, COX1: cyclooxygenase-1, eNOS: endothelial nitric oxide synthase, NO: 
nitric oxide, PLC: phospholipase C, sGC: soluble guanylate cyclase 
LPA accumulation in atherosclerotic plaques has been reported (67). Taking into 
consideration, that atherosclerosis is associated with endothelial dysfunction, in case of 
plaque rupture a large amount of LPA can be released into the local circulation, which 
acts on VSM and launches the aforementioned process. Moreover, accumulation of 
LPA has been demonstrated, systemically as well as locally in patient with ACS (409, 




ischemic phase. Potentially fatal consequences of this mechanism in cerebral or 
coronary vessels need not to be emphasized. 
Vasoconstrictor effects of LPA1-activation may be of importance after hemorrhage, 
where the natural agonist LPA in blood can also directly contact VSMCs without being 
engaged by functional endothelium. Studies conducted by Tigyi and colleagues in the 
90’s showed, that LPA, applied to the subarachnoid space of piglets elicited vasospasm 
(426, 468). Moreover, in a model of subarachnoid hemorrhage, 4 days after the injection 
of autologous blood or Endothelin-1, elevated levels of an LPA-like mediator could be 
detected in the cerebrospinal fluid (426). These results are in consistence with the 
actions found by the Chun-group in posthemorrhagic hydrocephalus, which was also 
mediated by LPA1 (348). Besides, with the same latency (i.e. 3-4 days after 
subarachnoid hemorrhage), as the LPA-like mediator was detected (426), inhibition of 
TXA2 synthesis alleviated the development of postsubarachnoidal vasospasm (478, 
479). Our results, together with the aforementioned studies provide a potential 
mechanism of action in case of vasospasm, a life-threatening complication after 
subarachnoid hemorrhage. Nonetheless, to verify this process and to point out potential 
intervening drug targets, further in vivo and clinical studies are essential. 
6.2. Role of S1P receptors in the regulation of the vascular tone 
In the next phase of our experiments, we focused on the vasoactive actions of S1P 
and its receptors. S1P applied on the resting tone had no effect on intact murine aortae. 
Furthermore, mechanical removal of the endothelium did not alter this outcome. 
However, if the endothelium-denuded vessels were precontracted with PE, S1P elicited 
marked vasoconstriction. 
The literature on this issue is also controversial. Although previous reports described 
a strong and long-lasting vasoconstriction, induced by S1P in canine basilar artery, in 
other species S1P proved to be less potent (439, 440). Furthermore, potency of S1P in 
other species was diverse in different vascular beds (440).  
S1P was also found to activate eNOS in rodent aortic rings, mesenteric arteries and 
various types of cell cultures (440). In these experiments, eNOS-activation was 
mediated by S1P3 in mice (441) and S1P1 in COS-7 cells (447). Involvement of the Gi-
PI3K and AMP-activated-kinase occurred as downstream signaling (440). Although, 




activation was partly reported in experiments conducted in endothelial cell cultures, 
which may not fully represent the functionality of the tissues as in vivo and ex vivo 
studies do. Furthermore, as formerly mentioned the S1P-induced effect may alter upon 
species and vascular beds (440). 
In our further experiments, we investigated the effect of S1P on PE-induced 
vasoconstriction. We found that 20 min incubation with S1P enhances PE-evoked 
contractions and this effect was maintained for at least 3 hours. 
Afterwards, we determined the expressional profiles of S1P GPCRs in freshly 
isolated murine thoracic aortic VSMCs. Our results indicate that S1P1, S1P2, S1P3, and 
S1P4 are expressed with S1P1 as most abundant. 
Thereafter we repeated the former experiments in vessels prepared from mice 
deficient in S1P2, or S1P3. Although, absence of S1P3 had no effect on S1P-induced 
potentiation of PE-induced vasoconstriction, the effect was abolished in S1P2 KO 
vessels. These results indicate that S1P acting on S1P2 interferes with α1-adrenergic 
signaling and mediates a long-lasting elevation in α1-mediated contractions. 
Interactions of S1P2 and α-adrenergic signaling have been emerged early at the time 
of generation of S1P2 KO mice. These animals showed decreased vascular tone, 
elevated blood-flow and consequently decreased resistance in the renal and mesenteric 
areas. Although, vessels of these mice exhibited decreased contractile responsiveness to 
α-adrenergic stimulation, this phenotype had no effect on the blood pressure of the 
animals (252). These results are in consistence with ours, however it must be pointed 
out, that in our case S1P2 signaling was not necessary to maintain the basal 
responsiveness to α-adrenergic stimuli but elicited further potentiation of it. Considering 
the fact, that S1P can be released from activated platelets (38, 149), the aforementioned 
mechanism can contribute to pathological states associated with blood coagulation, such 
as ischemic stroke or acute myocardial infarction. Hereby, it should be also noted, that 
the bulk of plasma S1P derives from the erythroid cell line as discussed in the 
introduction chapter, and that patients with acute myocardial infarction had lower 
circulating S1P levels than healthy controls (423). However, we hypothesize the effect 






In our experiments we sought to answer the question, how the EDG-like 
lysophospholipid receptors influence the vascular tone. According to our results, we can 
conclude that: 
 Activation of EDG-like lysophosphatidic acid (LPA) receptors elicits dose-
dependent vasorelaxation in the intact murine aorta, which is an endothelium 
dependent process and independent of prostanoids. 
 In the absence of endothelium, the EDG-like LPA agonist VPC31143 evoked dose-
dependent vasoconstriction, which was more pronounced in the abdominal than in 
the thoracic aorta. This effect is mediated by LPA1, which is relatively highly 
expressed in murine vascular smooth muscle cells. VPC31143 elicits TXA2 release 
in a Gi- and COX1-dependent manner, which, acting on its receptor (TP), causes 
vasoconstriction. The G proteins Gαq/11 and Gα12/13 are also involved in the signal 
transduction, probably downstream of the TP receptor. 
 Exposition to sphingosine 1-phosphate (S1P) potentiates α1-dependent 
vasoconstriction in murine aorta, in a long-lasting manner. This impact is mediated 





The endothelial differentiation gene (EDG) family is a group of G protein-coupled 
receptors (GPCR), which contains the first confirmed lysophospholipid receptors, 
specific for lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), (LPA1-3, 
S1P1-5). Both mediators and their receptors have a multitude of regulatory functions in 
the cardiovascular system, including angiogenesis, platelet shape-change, and ischemia-
reperfusion injury. The available literary data is however controversial and sparse on 
their role in vasoregulation. The aim of this study was to investigate, how the EDG-like 
lysophospholipid receptors influence the vascular tone. 
We showed that activation of the EDG-like LPA GPCRs has an ambiguous role in 
vasoregulation. In the intact precontracted murine aorta, the LPA1-3 agonist VPC31143 
elicited a dose-dependent vasorelaxation that was dependent of endothelial nitrogen-
oxide synthase activation and independent of the prostanoid system. In absence of the 
endothelium, the relaxation turned into vasoconstriction. Our qPCR results indicate that 
freshly isolated murine aortic smooth muscle cells (VSMC) express every known LPA 
GPCR. The vasoconstriction is mediated by LPA1, which elicits cyclooxygenase-1 
activation and thromboxane A2 (TXA2) release via Gi. TXA2 then acts on its receptor 
TP on VSMCs causing vasoconstriction. Gαq/11 and Gα12/13 are also involved in the 
process; however, the exact role should be further investigated. We hypothesize, that the 
Janus-faced activity of the EDG-like LPA GPCR may have a role in pathological 
processes associated with thrombus formation like ischemic stroke or myocardial 
infarction. 
Activation of S1P GPCRs has only negligible influence on the basal tone of the 
intact murine aorta, and also after removal of the endothelium. In precontracted aortae, 
S1P evoked vasoconstriction. Furthermore, incubation with S1P potentiated 
phenylephrine-induced contractions and the effect lasted at least for three hours. Our 
results indicate that freshly isolated murine aortic VSMCs express S1P1-4. Furthermore, 
we described, that activation of S1P2 is responsible for the potentiating effect of S1P. 
As S1P can also be released upon platelet activation, hence we conclude, that this 
potentiating effect of S1P may have a role under pathological conditions associated with 
blood coagulation and increased level of naturally occurring vasoconstrictors e.g. 





Az endotheliális differenciációs gén család (EDG) a G protein-kapcsolt receptorok 
egy csoportja, mely magába foglalja az elsőként leírt lizofoszfolipid receptorokat 
(LPA1-3 és S1P1-5), melyek természetes ligandjai a lizofoszfatidsav (LPA) és a 
szfingozin 1-foszfát (S1P). A kardiovaszkuláris rendszer működésében mindkét 
mediátor és receptoraik széleskörű szereppel bírnak, résztvevői olyan folyamatoknak, 
mint az angiogenezis, a thrombocyták alakváltozása vagy az iszkémia-reperfúziós 
károsodás. Ennek ellenére az irodalom szegényes és ellentmondásos e mediátorok és 
receptorok vazoregulációban betöltött szerepét illetően. Kutatásaink során arra kerestük 
a választ, befolyásolják-e az EDG családba tartozó LPA és S1P receptorok az értónust. 
Eredményeink szerint az LPA1-3 receptort aktiváló VPC31143-nak kettős hatása van 
az értónusra. Ép, előfeszített egér aortában vazorelaxációt okozott, mely hatás 
endotheliális nitrogén monoxid szintáz-függő volt, de független volt a prosztanoid 
rendszertől. Endothél-irtott erekben az agonista vazokonstrikciót okozott. Frissen izolált 
egér aorta ér simaizom sejtek (VSMC) az összes ismert LPA receptort expresszálják. 
Továbbá kimutattuk, hogy a kontrakció hátterében az LPA1 receptor aktivációja áll, 
mely thromboxán A2 (TXA2) felszabaduláshoz vezet Gi és cyclooxigenáz-1 aktiváción 
keresztül. A TXA2 saját, TP receptorán hatva vazokonstrikciót okoz. A folyamatban 
részt vesznek a Gαq/11 és Gα12/13 fehérjék, pontos szerepük azonban még tisztázásra vár. 
Eredményeink alapján feltételezhető, hogy az LPA receptorok Janus arcú hatásának 
szerepe lehet véralvadással összefüggő patológiás folyamatokban, mint az iszkémiás 
stroke és a szívinfarktus. 
Az S1P receptorok aktiválódásának nem volt érdemi hatása az erek alaptónusára és 
ez nem változott az endothelium eltávolítás után sem. Előfeszített erekben az S1P 
kontrakciót okozott. Kimutattuk, hogy az S1P-vel való inkubálás fokozza a fenilefrin 
által kiváltott kontrakciókat egér aortában. Eredményeink szerint frissen izolált egér 
aorta VSMC-kben az S1P1-4 receptorok fejeződnek ki. Megállapítottuk, hogy az S1P 
vazokonstrikciót potencírozó hatásáért az S1P2 receptor felelős. Figyelembe véve, hogy 
az S1P lokális koncentrációja megnőhet thrombocyta aktivációkor, feltételezzük, hogy 
az itt leírt folyamatoknak szerepük lehet olyan koagulációval összefüggő 
folyamatokban, ahol a vérben előforduló természetes konstriktorok szintje is 
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